WO2022010024A1 - Herbal composition for alleviating or treating atopic dermatitis, comprising natural composite ingredients, and method for preparing same - Google Patents
Herbal composition for alleviating or treating atopic dermatitis, comprising natural composite ingredients, and method for preparing same Download PDFInfo
- Publication number
- WO2022010024A1 WO2022010024A1 PCT/KR2020/010477 KR2020010477W WO2022010024A1 WO 2022010024 A1 WO2022010024 A1 WO 2022010024A1 KR 2020010477 W KR2020010477 W KR 2020010477W WO 2022010024 A1 WO2022010024 A1 WO 2022010024A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- parts
- weight
- distillate
- hot water
- water extract
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 75
- 201000008937 atopic dermatitis Diseases 0.000 title claims abstract description 42
- 206010012438 Dermatitis atopic Diseases 0.000 title claims abstract description 41
- 238000000034 method Methods 0.000 title claims abstract description 28
- 239000004615 ingredient Substances 0.000 title description 5
- 239000002131 composite material Substances 0.000 title 1
- 239000000284 extract Substances 0.000 claims abstract description 79
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 74
- 241000208340 Araliaceae Species 0.000 claims description 30
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 30
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 30
- 235000008434 ginseng Nutrition 0.000 claims description 30
- 229940124595 oriental medicine Drugs 0.000 claims description 28
- 238000004519 manufacturing process Methods 0.000 claims description 17
- 238000010438 heat treatment Methods 0.000 claims description 16
- 239000006228 supernatant Substances 0.000 claims description 16
- 235000007516 Chrysanthemum Nutrition 0.000 claims description 14
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 14
- 230000006872 improvement Effects 0.000 claims description 14
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims description 13
- 229910052737 gold Inorganic materials 0.000 claims description 13
- 239000010931 gold Substances 0.000 claims description 13
- 244000299790 Rheum rhabarbarum Species 0.000 claims description 10
- 235000009411 Rheum rhabarbarum Nutrition 0.000 claims description 10
- 240000006927 Foeniculum vulgare Species 0.000 claims description 9
- 235000004204 Foeniculum vulgare Nutrition 0.000 claims description 9
- 244000170916 Paeonia officinalis Species 0.000 claims description 9
- 235000006484 Paeonia officinalis Nutrition 0.000 claims description 9
- 239000008213 purified water Substances 0.000 claims description 9
- 244000111489 Gardenia augusta Species 0.000 claims description 8
- 210000004207 dermis Anatomy 0.000 claims description 8
- 240000000249 Morus alba Species 0.000 claims description 7
- 235000008708 Morus alba Nutrition 0.000 claims description 7
- 230000036541 health Effects 0.000 claims description 7
- 239000000498 cooling water Substances 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 210000003491 skin Anatomy 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 238000003809 water extraction Methods 0.000 claims description 5
- 240000002045 Guettarda speciosa Species 0.000 claims description 4
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 4
- 238000004821 distillation Methods 0.000 claims description 3
- 239000011122 softwood Substances 0.000 claims description 3
- 244000270834 Myristica fragrans Species 0.000 claims 2
- 235000009421 Myristica fragrans Nutrition 0.000 claims 2
- 239000001702 nutmeg Substances 0.000 claims 2
- 210000002510 keratinocyte Anatomy 0.000 abstract description 8
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 7
- 230000003078 antioxidant effect Effects 0.000 abstract description 7
- 230000007774 longterm Effects 0.000 abstract description 6
- 238000003860 storage Methods 0.000 abstract description 6
- 239000003755 preservative agent Substances 0.000 abstract description 5
- 206010040880 Skin irritation Diseases 0.000 abstract description 4
- 239000000654 additive Substances 0.000 abstract description 4
- 230000036556 skin irritation Effects 0.000 abstract description 4
- 231100000475 skin irritation Toxicity 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 4
- 244000144927 Aloe barbadensis Species 0.000 abstract 1
- 235000002961 Aloe barbadensis Nutrition 0.000 abstract 1
- 241000213006 Angelica dahurica Species 0.000 abstract 1
- 241000628997 Flos Species 0.000 abstract 1
- 241000319057 Kalopanax septemlobus Species 0.000 abstract 1
- 235000011399 aloe vera Nutrition 0.000 abstract 1
- 231100000956 nontoxicity Toxicity 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 14
- 239000006210 lotion Substances 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 10
- 239000002609 medium Substances 0.000 description 9
- 206010003645 Atopy Diseases 0.000 description 7
- 102000004890 Interleukin-8 Human genes 0.000 description 7
- 108090001007 Interleukin-8 Proteins 0.000 description 7
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 6
- 229920006008 lipopolysaccharide Polymers 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 241000411851 herbal medicine Species 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 239000000686 essence Substances 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 229940107131 ginseng root Drugs 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 239000002574 poison Substances 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 208000017520 skin disease Diseases 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 102000015696 Interleukins Human genes 0.000 description 3
- 108010063738 Interleukins Proteins 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- 241000233866 Fungi Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 230000010757 Reduction Activity Effects 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 239000010903 husk Substances 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 230000004719 natural immunity Effects 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 235000015701 Artemisia arbuscula Nutrition 0.000 description 1
- 235000002657 Artemisia tridentata Nutrition 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- 208000012657 Atopic disease Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000723353 Chrysanthemum Species 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 206010014198 Eczema infantile Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 240000006890 Erythroxylum coca Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 244000230712 Narcissus tazetta Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 244000171263 Ribes grossularia Species 0.000 description 1
- 235000002357 Ribes grossularia Nutrition 0.000 description 1
- 208000006981 Skin Abnormalities Diseases 0.000 description 1
- 230000029662 T-helper 1 type immune response Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 235000019714 Triticale Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000008957 cocaer Nutrition 0.000 description 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940096397 interleukin-8 Drugs 0.000 description 1
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000021148 salty food Nutrition 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 238000010517 secondary reaction Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 239000008234 soft water Substances 0.000 description 1
- 235000021259 spicy food Nutrition 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000029069 type 2 immune response Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 241000228158 x Triticosecale Species 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
Definitions
- the present invention relates to an oriental medicine composition for the improvement or treatment of atopic dermatitis containing a natural complex component and a method for manufacturing the same, and more specifically, to a composition containing a natural complex ingredient, which has strong anti-inflammatory and antioxidant activity, and is toxic to keratinocytes. It relates to an oriental medicine composition suitable for use in the improvement or treatment of atopic dermatitis and a method for manufacturing the same, since the use of chemical preservatives and additives that can cause skin irritation can be avoided due to excellent long-term storage stability.
- Atopic dermatitis is a chronic dermatitis that occurs frequently in people with a genetic predisposition to cause eczema, hayfever, asthma, allergy, etc. It is called fetal fever and starts as infantile eczema and has a chronic, recurrent course.
- atopic dermatitis Today, the general treatment of atopic dermatitis is aimed at controlling pruritus and preventing the occurrence of secondary lesions, and depending on the drug administration method, an external method, an oral method, and an immunization method are used.
- external methods a method of washing the skin, a method of applying a steroid-based ointment, and a method of applying a moisturizer are used.
- steroids are a kind of adrenal corticosteroid, and although the effect is very fast, various side effects such as atrophy of the skin and the possibility of growth retardation in pediatric patients when used for a long period of time are problematic.
- Moisturizer refers to applying cosmetics to supply and maintain moisture to dry skin.
- Antihistamines, steroid-based drugs, or herbal medicines are mainly used for the treatment of atopic dermatitis, which is mainly used as an oral method.
- Immunity is the process of adjusting or inducing the surrounding environment to naturally develop the body's immunity.
- the over-the-counter composition contains conventionally developed herbal extracts or herbal preparations to treat atopic diseases and other skin diseases (psoriasis, eczema). When discontinuing use, serious side effects for dilated disease and tertiary bacterial infection may develop.
- the characteristics of the immune system in children and adults can be related to the development and pathological characteristics of atopy. 70-80% of newborns in Korea experience fetal fever. Most of them naturally tend to be treated as they enter childhood. However, according to some reports, 20-30% of them progress to atopy in children. This phenomenon is a natural change of the immune system, that is, as the specific immunity of infancy enters childhood, the natural immunity is restored and atopy is cured.
- the immunological characteristic of this period can be seen as the period when natural immunity is actively growing. In other words, it is a process in which the natural immune system grows as children experience fever-like symptoms. Therefore, it is not advisable to misuse or abuse antipyretics or antibiotics when children have cold or fever symptoms. In adults, this is a period in which both the natural and specific immunity are mature to some degree. In other words, whether healthy or not, the immune system is fixed to some degree.
- heat poison not only causes skin abnormalities, but also causes various complications by lowering the body's immunity, they argue that it is necessary to find the cause of atopic dermatitis and treat it fundamentally rather than just treating the symptoms.
- basic treatment such as releasing heat poison that causes atopic dermatitis and increasing self-reliance to fight allergies can prevent recurrence.
- Inflammatory cells are mainly cells involved in secondary reactions such as macrophages and eosinophils. It is believed to have penetrated into This disease is strongly associated with the TH1/TH2 immune response.
- naive T cells are exposed to interleukin (IL)-12, IL-18, or IL-4 to differentiate into TH1 or TH2 cells.
- TH1 cells secrete inflammatory cytokines interferon-gamma (IFN- ⁇ ) and tumor necrosis factor-alpha (TNF- ⁇ ) and suppress TH2, whereas TH2 cells contain IL-4, IL It secretes -5 and IL-13 and suppresses TH1 response.
- IFN- ⁇ interferon-gamma
- TNF- ⁇ tumor necrosis factor-alpha
- TH2 cells contain IL-4, IL It secretes -5 and IL-13 and suppresses TH1 response.
- IL-8 is a cytokine mainly associated with inflammation, and IL-8, which is known
- This research team researches and tests various medicinal herbs and natural materials used in oriental medicine, and when extracting natural ingredients with hot water, cooling and recovering the distillation components that are volatilized at a certain temperature or higher produces a hydrothermal distillation fraction rich in essential oils, aromatics and antioxidants. It was found that it can be secured, and the present invention was completed by compounding a composition showing the best efficacy for the improvement or treatment of atopic skin diseases.
- the problem to be solved by the present invention is to provide an oriental medicine composition useful for the improvement or treatment of atopic dermatitis because it contains natural complex ingredients and has excellent anti-inflammatory and antioxidant activity and no side effects.
- Another object to be solved by the present invention is to provide a method for preparing an oriental medicine composition for improving or treating atopic dermatitis as described above.
- An oriental medicine composition for improving or treating atopic dermatitis is 3-5 parts by weight of high ginseng, 3-5 parts by weight of ginseng, 4-6 parts by weight of gold, 4-6 parts by weight of white paper It contains the distillate of the hot water extract of a mixture comprising parts, presbytery, 3-5 parts by weight, haedongpi, 3-5 parts by weight, and softwood, 5-7 parts by weight.
- composition may further include the hot water extract in an amount of 10-30 parts by weight based on 70-90 parts by weight of the distillate.
- the oriental medicine composition for improving or treating atopic dermatitis for solving the above problems is 3-5 parts by weight of a distillate of hot ginseng extract, 3-5 parts by weight of a distillate of hot water extract of Gossam, 4-6 parts by weight of distillate of golden hot water extract, 4-6 parts by weight of distillate of white paper hot water extract, 3-5 parts by weight of distillate of presbytery hot water extract, 3-5 parts by weight of distillate of haedongpi hot water extract and Yeongyo hot water 5-7 parts by weight of the distillate of the extract.
- the composition comprises 4-6 parts by weight of distillate of Duchung hot water extract, 4-6 parts by weight of distillate of peony hot water extract, 1-3 parts by weight of distillate of Mokhyang hot water extract, and 1-3 parts by weight of distillate of Angelica hot water extract.
- distillate of dermis hot water extract 1-3 parts by weight of distillate of dermis hot water extract, 4-6 parts by weight of distillate of fennel hot water extract, 5-7 parts by weight of distillate of health hot water extract, 3-5 parts by weight of distillate of husk hot water extract, chrysanthemum 4-6 parts by weight of the distillate of the hot water extract, 4-6 parts by weight of the distillate of the ginseng root hot water extract, 4-6 parts by weight of the distillate of the Zimo hot water extract, 1-3 parts by weight of the distillate of the Gokgisaeng hot water extract, Hwangbaek hot water 5-7 parts by weight of distillate of extract, 3-5 parts by weight of distillate of Gobon hot water extract, 3-5 parts by weight of distillate of rhubarb hot water extract, 3-5 parts by weight of distillate of gardenia hot water extract, Tobongryeong hot water extract It may further include at least one selected from the group consisting of 3-5 parts by weight of the distillate and 5-7
- the method of manufacturing an oriental medicine composition for improvement or treatment of atopic dermatitis is (a) 3-5 parts by weight of high ginseng, 3-5 parts by weight of ginseng, 4-6 parts by weight of gold parts, 4-6 parts by weight of white paper, 3-5 parts by weight of presbytery, 3-5 parts by weight of haedongpi, and 5-7 parts by weight of yeonkyo to obtain an extract by hot water extraction, and (b) heating the extract and cooling the resulting vapor to obtain a distillate.
- the manufacturing method may further include (c) mixing 10-30 parts by weight of the extract remaining after the heating to 70-90 parts by weight of the distillate.
- step (a) the high ginseng, gooseberry, gold, white paper, presbytery, haedongpi and Yeongyo are put in purified water and heated to 80-100 ° C. for 8-48 hours using an extractor, and the heated It may include the step of obtaining the extract by filtration.
- the step (b) may include heating the extract to 90-100° C. and liquefying the steam produced by 4-10° C. cooling water pipe, and liquefying the liquefied product at 8,000-14,000 rpm and 2- It may include the step of removing the solid by centrifugation at 8 ° C. for 10-50 minutes, and taking the supernatant to obtain the distillate.
- step (a) 4-6 parts by weight of duchung, 4-6 parts by weight of peony, 1-3 parts by weight of mulberry, 1-3 parts by weight of angelica, 1-3 parts by weight of dermis, 4-6 parts by weight of fennel , Health 5-7 parts by weight, Hucchini 3-5 parts by weight, Chrysanthemum 4-6 parts by weight, Root Root 4-6 parts by weight, Zinc 4-6 parts by weight, Grain ginseng 1-3 parts by weight, Hwangbaek 5-7 parts by weight , 3-5 parts by weight of Gobon, 3-5 parts by weight of rhubarb, 3-5 parts by weight of gardenia, 3-5 parts by weight of Tobongryeong and 5-7 parts by weight of Sambaekcho by further mixing at least one selected from the group consisting of hot water extraction can
- a method of manufacturing an oriental medicine composition for improvement or treatment of atopic dermatitis is (a) hot water extraction of Gosam, Goehwa, Gold, White paper, Hwangbaek, Gobon, Haedongpi and Yeongyo, respectively.
- each extract (b) heating each extract to cool the produced vapor to obtain each distillate, and (c) 3-5 parts by weight of the distillate of high ginseng, distillate 3 of Gohwa -5 parts by weight, 4-6 parts by weight of distillate of gold, 4-6 parts by weight of distillate of white paper, 3-5 parts by weight of distillate of presbytery, 3-5 parts by weight of distillate of thawed blood and 5 parts of distillate of Yeongyo -7 parts by weight are mixed with each other.
- the step (a) is a step of putting each of the dried ginseng, Gohwa, gold, white paper, presbytery, haedongpi and Yeongyo in purified water and heating it to 80-100 ° C. for 8-48 hours using an extractor, and the heated It may include the step of obtaining each extract by filtration.
- step (b) is a step of liquefying the steam produced by heating each extract to 90-100 °C with a cooling water pipe of 4-10 °C, and 8,000-14,000 rpm and 2-8 °C of the liquefied It may include the step of removing the solid content by centrifugation for 10-50 minutes and taking the supernatant to obtain each of the distillates.
- step (c) 4-6 parts by weight of distillate of duchung, 4-6 parts by weight of distillate of peony, 1-3 parts by weight of distillate of mulberry, 1-3 parts by weight of distillate of angelicae, dermis 1-3 parts by weight of distillate, 4-6 parts by weight of distillate of fennel, 5-7 parts by weight of distillate of health, 3-5 parts by weight of distillate of husk, 4-6 parts by weight of distillate of chrysanthemum, garlic root 4-6 parts by weight of the distillate, 4-6 parts by weight of the distillate of Zimo, 1-3 parts by weight of the distillate of Gokgi-saeng, 5-7 parts by weight of the distillate of Hwangbaek, 3-5 parts by weight of the distillate of Gobon; At least one selected from the group consisting of 3-5 parts by weight of distillate of rhubarb, 3-5 parts by weight of distillate of gardenia, 3-5 parts by weight of distillate of Tobongryeong
- the method for preparing an oriental medicine composition for improving or treating atopic dermatitis may further include further purifying the obtained distillate using an ultrafiltration membrane or chromatography.
- the density of the above-described distillate or supernatant may be approximately 1 kg/L, that is, approximately or substantially the same as the density of purified water. Accordingly, 'parts by weight', which is the content unit of the above-described distillate or supernatant, may be substantially the same as 'parts by volume'.
- the oriental medicine composition according to the embodiments of the present invention contains natural complex ingredients, so it has strong anti-inflammatory and antioxidant activity, is non-toxic to keratinocytes, and has excellent long-term storage stability, which can cause skin irritation. Since the use of preservatives and additives can be avoided, it is suitable for use in the improvement or treatment of atopic dermatitis.
- 1 is a graph measuring the toxicity to keratinocyte cells of the oriental medicine composition of the present invention according to an experimental example of the present invention.
- Figure 2 is a graph measuring the amount of nitric oxide (NO) production reduction activity of the oriental herbal composition of the present invention according to an experimental example of the present invention.
- FIG. 3 is a graph measuring the reduction activity of the inflammatory cytokines (IL-8, TNF- ⁇ ) of the herbal composition of the present invention according to an experimental example of the present invention.
- the term 'prevention' refers to inhibiting the occurrence of a disease or disease in an individual who has never been diagnosed with a disease or disease, but may be afflicted with such disease or disease.
- 'treatment' or 'improvement' refers to (a) inhibition of the development (exacerbation) of a disease or disease, (b) alleviation of the disease or disease, or (c) elimination of the disease or disease in an individual.
- the term 'subject' refers to a mammal, including a human, having a disease whose symptoms can be improved by administering the composition of the present invention.
- the oriental medicinal composition of the present invention has an improvement or therapeutic effect on atopic dermatitis, and in the present specification, 'atopic dermatitis' is used in a broad sense including atopic dermatitis, skin disease, psoriasis, eczema, itching, and the like.
- the herbal composition of the present invention may be composed of one or more formulations selected from the group consisting of a liquid extract, a concentrated liquid extract, a freeze-dried powder, and a spray-dried powder.
- the herbal composition of the present invention is a transdermal absorbent (external skin ointment), water soap, soap, essence, gel, liquid detergent, lotion, foam, soft water, lotion, cleansing foam, cleansing lotion, cleansing cream, pack, massage cream , emollient cream, emollient lotion, lotion essence, astringent, water-soluble liquid, foundation, makeup base, body lotion, astringent lotion, softening lotion, nourishing lotion, treatment, skin lotion, milk It may be one or more formulations selected from the group consisting of lotions, nutritional lotions, nutritional essences, oil-in-water (O/W) types and water-in-oil (W/O) types.
- the herbal composition of the present invention may be included in an amount of 0.005-95 wt% based on the total composition of the formulation.
- An herbal composition was prepared in the same manner as in Example 1, except that 3 L of the hot water extract remaining after heating in Example 1 was mixed with 7 L of the distillate and centrifuged.
- daffodil As a raw material for herbal medicines, 50 g of daffodil, 50 g of peony, 20 g of mulberry, 20 g of angelica, 20 g of ginseng, 50 g of fennel, 60 g of health, 40 g of green peppercorns, 50 g of chrysanthemum, 50 g of ginseng root, 50 g of ginseng root, 20 g of ginseng g, Hwangbaek 60 g, Gobon 40 g, and Sambaekcho 60 g, except that an oriental medicine composition was prepared in the same manner as in Example 1 above.
- each raw material After thoroughly washing the raw materials of medicinal herbs of ginseng, Gohwa, gold, white paper, presbytery, haedongpi and Yeongyo with purified water, each raw material is separately put into a boiling water still filled with 20 L of purified water and heated at about 80-100 ° C for 30 hours. Each hot water extract was obtained. Herbal medicines used for extraction were removed by filtration, and each distillate was obtained using a cooling water tube of about 4-10 °C while heating each hot water extract to about 90-100 °C. Each distillate was centrifuged at 12,000 rpm and 4° C. for 30 minutes to remove solids, and each supernatant was collected.
- An oriental medicine composition was prepared by mixing 0.4 L of high ginseng supernatant, 0.4 L of Goehwa supernatant, 0.5 L of golden supernatant, 0.5 L of white paper supernatant, 0.4 L of presbytery supernatant, 0.4 L of Haedongpi supernatant and 0.6 L of Yeongyo supernatant.
- the toxicity of the oriental herbal composition of the present invention to keratinocytes was tested as follows.
- human keratinocyte cell line HaCaT
- DMEM Dulbecco's modified Eagle's medium
- FBS Fetal bovine serum
- the medium was changed to a serum-free medium and cultured for 16-24 hours, and then the medium containing the composition of the above example was exchanged. After 48 hours, it was exchanged with a medium containing 10% MTT (Tetrazolium-based colorimetric) solution. After incubation for 2-4 hours, the medium was removed and the precipitate remaining under the culture dish was dissolved with DMSO (dimethyl sulfoxide).
- DMSO dimethyl sulfoxide
- the oriental medicine composition of the present invention does not show toxicity to keratinocytes.
- DMEM Dulbecco's modified Eagle's medium
- FBS fetal bovine serum
- penicillin and streptomycin 100 unit/ml penicillin and streptomycin at a concentration of 1 ⁇ 10 6 cell/ml in a 96-well plate. Inoculated and incubated overnight at 37 °C, 5% CO 2 . The next day, the medium was removed and replaced with a fresh medium, and cells were treated with 50 ⁇ l of the composition of the above example.
- a medium containing 50 ⁇ l (1 ⁇ g/ml) of LPS (lipopolysaccharide) was treated and incubated in an incubator (5% CO 2 , 37 ° C.) for 24 hours.
- PBS phosphate buffered saline
- Griess reagent I NBD solution
- Griess reagent II Sulfaniliamide solution
- the concentration of nitric oxide (NO) was calculated using a standard curve (0-100 ⁇ M) of sodium nitrite.
- the oriental herbal compositions of the present invention have excellent antioxidant and anti-inflammatory activity because they reduced the amount of NO produced by LPS by 40-50% or more.
- the anti-inflammatory activity of the herbal composition of the present invention was measured as follows.
- RAW 264.7 cells cultured as in the above experimental example were first treated with the composition of the above example, then LPS (lipopolysaccharide) was treated at a concentration of 1 ⁇ g/ml and cultured for 24 hours, the supernatant was recovered and IL-8 using an ELISA kit. (interleukin-8) was measured. After reacting using an antibody for detection bound to Avidin, absorbance was measured at 450 nm with a microplate reader, and phosphate buffered saline (PBS) was used as a control.
- PBS phosphate buffered saline
- the secretion amount of IL-8 and the expression level of TNF- ⁇ were as shown in FIG. 3, and as shown in FIG. 3, the oriental medicine compositions of the present invention showed the production of IL-8 and TNF- ⁇ , which are inflammatory cytokines promoted by LPS. It can be seen that there is excellent anti-inflammatory activity because it is reduced by more than 40-50%.
- 0.1 ml of the composition of the above example was smeared on Letheen agar and left at 30° C. for 48 hours to check whether or not bacteria were propagated. It was checked whether The presence of bacteria and fungi was confirmed immediately after preparation of the composition of the above example and after leaving it alone.
- the oriental herbal composition of the present invention has excellent long-term storage stability because microorganisms do not propagate even when stored for a long period at room temperature without a separate preservative, so chemical preservatives and additives that may cause skin irritation can be omitted.
- the present invention can be used in the industrial field related to an oriental medicine composition for improving or treating atopic dermatitis and a method for manufacturing the same.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a herbal composition for alleviating or treating atopic dermatitis, and to a method for preparing same, and more specifically, to a herbal composition suitable for use in the alleviation or treatment of atopic dermatitis, which comprises a distillate of a hot-water extract of a mixture comprising 3-5 parts by weight of Sophorae radix, 3-5 parts by weight of Sophorae Flos, 4-6 parts by weight of Scutellariae Radix, 4-6 parts by weight of Angelica dahurica Radix, 3-5 parts by weight of Aloe barbadensis, 3-5 parts by weight of Kalopanax pictus, and 5-7 parts by weight of Forsythiae Fructus, and shows potent anti-inflammatory and antioxidant activities and no toxicity to keratinocytes, and has excellent long-term storage stability, which thus eliminates the need for the use of chemical preservatives and additives that may cause skin irritation. In addition, the present invention relates to a method of preparing the herbal composition.
Description
본 발명은 천연 복합성분을 함유하는 아토피 피부염의 개선 또는 치료용 한방 조성물 및 그 제조 방법에 관한 것으로서, 구체적으로는 천연 복합성분을 함유하여 항염 및 항산화 활성이 강력하고, 각질형성세포에 대한 독성이 없으며, 장기 보존 안정성이 우수하여 피부 자극을 유발할 수 있는 화학 방부제, 첨가제 등의 사용을 피할 수 있어 아토피 피부염의 개선 또는 치료에 사용하기 적합한 한방 조성물 및 이의 제조 방법에 관한 것이다.The present invention relates to an oriental medicine composition for the improvement or treatment of atopic dermatitis containing a natural complex component and a method for manufacturing the same, and more specifically, to a composition containing a natural complex ingredient, which has strong anti-inflammatory and antioxidant activity, and is toxic to keratinocytes. It relates to an oriental medicine composition suitable for use in the improvement or treatment of atopic dermatitis and a method for manufacturing the same, since the use of chemical preservatives and additives that can cause skin irritation can be avoided due to excellent long-term storage stability.
'아토피(atopy)'는 1925년 코카(Coca)라는 학자가 처음으로 사용한 용어로, 음식물이나 기타 흡입성 물질에 대한 선천성 알러지(allergy) 반응을 의미한다. 'atopy'는 그리스어로 '알 수 없는', '괴상한'이라는 뜻으로 그 의미에서도 알 수 있듯 정확한 원인은 알 수 없고, 치료가 힘든 난치성 질환이다. 아토피성 피부염(atopic dermatitis)은 보통 습진(eczema), 고초열(hayfever), 천식(asthma), 알레르기(allergy) 등을 잘 일으키는 유전적 경향을 보이는 체질을 가진 사람에게서 많이 발생되는 만성 피부염으로 흔히 태열이라 부르고 유아 습진으로 시작, 만성, 재발성 경과를 보인다.'Atopy' is a term first used by a scholar named Coca in 1925, and refers to a congenital allergic reaction to food or other inhalable substances. 'atopy' is a Greek word that means 'unknown' or 'weird'. Atopic dermatitis is a chronic dermatitis that occurs frequently in people with a genetic predisposition to cause eczema, hayfever, asthma, allergy, etc. It is called fetal fever and starts as infantile eczema and has a chronic, recurrent course.
아토피의 발생 원인은 아직까지 확실히 밝혀져 있지 않다. 다만 유전적, 면역학적 요인이 깊숙이 관계되리라 생각되며 동시에 환경적, 사회적, 정신적 요인 등 다양한 주변인자들도 연관이 있으리라고 생각되고 있다.The cause of atopy is not yet known with certainty. However, genetic and immunological factors are thought to be deeply related, and at the same time, various peripheral factors such as environmental, social, and psychological factors are also thought to be related.
오늘날 일반적인 아토피성 피부염의 치료는 소양감의 조절, 2차 병변 발생의 방지를 목적으로 하고, 약물투여 방법에 따라 외용 방법, 내복 방법, 그리고 면역 방법 등이 사용되고 있다. 외용 방법으로는 피부를 세정하는 방법, 스테로이드 계열의 연고제를 바르는 방법, 그리고 보습제를 바르는 방법 등이 사용되고 있다. 특히 스테로이드는 일종의 부신피질 호르몬제로서 효과는 매우 빠르지만, 장기간 사용했을 때 피부의 위축이나 소아 환자에서 성장지연의 가능성 등 각종 부작용이 문제되고 있다. 보습제는 건조한 피부에 수분을 공급 및 유지하기 위한 화장품류를 바르는 것을 말한다. 내복 방법으로 주로 사용하는 아토피 치료약은 항히스타민제, 스테로이드계 의약품 혹은 한방 소재 치료약이 주로 사용되고 있다. 면역 방법은 신체의 면역력을 자연적으로 길러줄 수 있도록 주변 환경을 조정하거나 유도하는 것이다Today, the general treatment of atopic dermatitis is aimed at controlling pruritus and preventing the occurrence of secondary lesions, and depending on the drug administration method, an external method, an oral method, and an immunization method are used. As external methods, a method of washing the skin, a method of applying a steroid-based ointment, and a method of applying a moisturizer are used. In particular, steroids are a kind of adrenal corticosteroid, and although the effect is very fast, various side effects such as atrophy of the skin and the possibility of growth retardation in pediatric patients when used for a long period of time are problematic. Moisturizer refers to applying cosmetics to supply and maintain moisture to dry skin. Antihistamines, steroid-based drugs, or herbal medicines are mainly used for the treatment of atopic dermatitis, which is mainly used as an oral method. Immunity is the process of adjusting or inducing the surrounding environment to naturally develop the body's immunity.
일반의약품 조성물은 종래의 개발된 생약추출물 또는 생약제제를 함유하여 아토피성질환 및 기타 피부질환(건선, 습진) 등의 치료를 하는데, 스테로이드 및 항히스타민 성분으로 인한 피부 침착, 착색 및 심한 가려움증 등의 부작용을 유발하며, 사용을 중지할 시 확장성 질환에 대한 심각한 부작용과 3차 세균 감염으로 발전될 수 있다.The over-the-counter composition contains conventionally developed herbal extracts or herbal preparations to treat atopic diseases and other skin diseases (psoriasis, eczema). When discontinuing use, serious side effects for dilated disease and tertiary bacterial infection may develop.
소아와 성인기의 면역 체계의 특성이 아토피의 발생 및 병리적 특성과 연관될 수 있다. 우리나라 신생아의 70-80%가 태열을 경험한다. 이들 중의 대부분은 자연스럽게 소아기에 접어들면서 치료되는 경향을 보인다. 그러나 일부 보고에 의하면 이들 중의 20-30%는 소아 아토피로 진행이 된다고 한다. 이러한 현상은 면역계의 자연스러운 변화인데, 즉 유아기의 특이면역이 소아기에 접어들면서 자연면역이 회복이 되면서 아토피는 치유가 되는 것이다. The characteristics of the immune system in children and adults can be related to the development and pathological characteristics of atopy. 70-80% of newborns in Korea experience fetal fever. Most of them naturally tend to be treated as they enter childhood. However, according to some reports, 20-30% of them progress to atopy in children. This phenomenon is a natural change of the immune system, that is, as the specific immunity of infancy enters childhood, the natural immunity is restored and atopy is cured.
그래서 이 시기의 면역학적인 특징은 자연면역이 활발하게 성장을 하는 시기라고 볼 수 있다. 즉, 아이들이 감기와 같은 발열증상들을 경험하면서 자연 면역계가 성장하는 과정인 것이다. 그러므로 아이들이 감기나 발열증상이 있을 때 해열제나 항생제를 오·남용하는 것은 바람직한 것이 아니다. 성인의 경우, 이 시기는 자연 면역계와 특이 면역 모두 어느 정도는 성숙되어 있는 시기다. 즉, 건강하든 건강하지 않든 면역계는 어느 정도 고착화되어 있는 것이다.Therefore, the immunological characteristic of this period can be seen as the period when natural immunity is actively growing. In other words, it is a process in which the natural immune system grows as children experience fever-like symptoms. Therefore, it is not advisable to misuse or abuse antipyretics or antibiotics when children have cold or fever symptoms. In adults, this is a period in which both the natural and specific immunity are mature to some degree. In other words, whether healthy or not, the immune system is fixed to some degree.
양의학과 한의학에서는 아토피 피부염이 생기는 원인에 대해 '몸 안에 뭉친 열이 독을 만들었기 때문'이라고 보고 있다. 몸속 깊숙이 숨어 있던 열독이 피부층까지 올라와 각종 트러블을 일으키는 것이다. 따라서 열독이 풀리지 않는 한 아토피 피부염은 계속 재발할 수밖에 없다. 특히 임신 중에 맵고 짠 음식이나 과도한 카페인, 알코올, 인스턴트, 기름진 음식 등을 많이 섭취했거나, 자궁 안에 노폐물이 많이 쌓였거나, 자궁이 약한 경우 태내에 열이 쌓여 태아에게 아토피 피부염을 유발한다고 보고 있다. 열독은 피부 이상만을 일으키는 것이 아니라 몸의 면역력을 떨어뜨려 각종 합병증을 유발시키므로 단순히 증상만 치료하는 것이 아니라 아토피 피부염의 원인을 찾아 근본적인 치료를 해야 한다고 주장한다. 즉, 아토피 피부염의 원인이 되는 열독을 풀어 주고, 알레르기에 대항할 수 있는 자생력을 키우는 등 근본치료를 해야 재발을 막을 수 있다고 이야기하고 있다.Western medicine and oriental medicine believe that the cause of atopic dermatitis is 'because the heat accumulated in the body made poison'. The heat poison that was hidden deep inside the body rises to the skin layer and causes various troubles. Therefore, unless heat poisoning is resolved, atopic dermatitis will inevitably continue to recur. In particular, if you consume a lot of spicy and salty food, excessive caffeine, alcohol, instant food, or oily food during pregnancy, or if a lot of waste products accumulate in the uterus, or if the uterus is weak, heat builds up in the uterus and causes atopic dermatitis in the fetus. Because heat poison not only causes skin abnormalities, but also causes various complications by lowering the body's immunity, they argue that it is necessary to find the cause of atopic dermatitis and treat it fundamentally rather than just treating the symptoms. In other words, it is said that basic treatment such as releasing heat poison that causes atopic dermatitis and increasing self-reliance to fight allergies can prevent recurrence.
염증세포들은 주로 대식세포, 호산구와 같은 속발반응에 관여하는 세포들이며 이들은 아토피성 피부염의 급성기에 존재하던 세포들에서 생성된 IL-1 과 TNF-α과 같은 사이토카인(cytokine)의 직접적인 영향으로 피부에 침투한 것으로 여겨지고 있다. 이 질환은 TH1/TH2 면역 반응과 큰 연관이 있다. 항원이 제시되면 원시 T 세포(naive T cell)은 인터루킨(interleukin, IL)-12, IL-18, 또는 IL-4에 노출되어 TH1이나 TH2 세포로 분화된다. TH1 세포는 염증성 사이토카인인 인터페론 감마(interferon-gamma, IFN-γ)와 종양괴사인자(tumor necrosis factor-alpha, TNF-α)를 분비하며 TH2를 억제하는 반면, TH2 세포는 IL-4, IL-5, IL-13 등을 분비하며 TH1 반응을 억제한다. 특히, IL-8은 주로 염증과 연관이 되는 사이토카인인데, 산화적 스트레스에 의해 증가되는 것으로 알려진 IL-8은 국소적 염증에 중요한 매개 변수가 된다. Inflammatory cells are mainly cells involved in secondary reactions such as macrophages and eosinophils. It is believed to have penetrated into This disease is strongly associated with the TH1/TH2 immune response. When antigen is presented, naive T cells are exposed to interleukin (IL)-12, IL-18, or IL-4 to differentiate into TH1 or TH2 cells. TH1 cells secrete inflammatory cytokines interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α) and suppress TH2, whereas TH2 cells contain IL-4, IL It secretes -5 and IL-13 and suppresses TH1 response. In particular, IL-8 is a cytokine mainly associated with inflammation, and IL-8, which is known to be increased by oxidative stress, is an important parameter for local inflammation.
최근 아토피성 피부염 및 피부질환에 관한 식물, 광물, 동물성의 천연물 소재 연구가 활발히 진행되고 있는 현황이다. 그러나 아직까지 아토피 피부염에 뛰어난 효능을 보이는 동시에 부작용이 없고 사용이 용이한 의약 조성물이나, 화장품 조성물 또는 식품조성물 등은 없는 실정이다. Recently, research on natural materials of plants, minerals, and animals for atopic dermatitis and skin diseases is being actively conducted. However, there is still no pharmaceutical composition, cosmetic composition or food composition that shows excellent efficacy in atopic dermatitis and has no side effects and is easy to use.
본 연구팀은 한방에서 사용되는 다양한 약재와 천연 소재들을 연구하고 실험하여, 천연 성분을 열수 추출 시 일정 온도 이상에서 휘발되는 증류성분을 냉각 회수하면 정유성분, 방향족성분 및 항산화성분이 풍부한 열수 증류 분획을 확보할 수 있다는 것을 발견하고, 아토피성 피부질환의 개선 또는 치료에 가장 좋은 효능을 나타내는 조성물을 배합함으로써 본 발명을 완성하였다.This research team researches and tests various medicinal herbs and natural materials used in oriental medicine, and when extracting natural ingredients with hot water, cooling and recovering the distillation components that are volatilized at a certain temperature or higher produces a hydrothermal distillation fraction rich in essential oils, aromatics and antioxidants. It was found that it can be secured, and the present invention was completed by compounding a composition showing the best efficacy for the improvement or treatment of atopic skin diseases.
이에, 본 발명이 해결하고자 하는 과제는 천연 복합성분을 함유하여 항염 및 항산화 활성이 우수하고 부작용이 없어 아토피 피부염의 개선 또는 치료에 유용한 한방 조성물을 제공하는 것이다.Accordingly, the problem to be solved by the present invention is to provide an oriental medicine composition useful for the improvement or treatment of atopic dermatitis because it contains natural complex ingredients and has excellent anti-inflammatory and antioxidant activity and no side effects.
본 발명이 해결하고자 하는 다른 과제는 위와 같은 아토피 피부염의 개선 또는 치료용 한방 조성물을 제조하는 방법을 제공하는 것이다. Another object to be solved by the present invention is to provide a method for preparing an oriental medicine composition for improving or treating atopic dermatitis as described above.
본 발명의 과제들은 이상에서 언급한 기술적 과제로 제한되지 않으며, 언급되지 않은 또 다른 기술적 과제들은 아래의 기재로부터 당업자에게 명확하게 이해될 수 있을 것이다.The problems of the present invention are not limited to the technical problems mentioned above, and other technical problems not mentioned will be clearly understood by those skilled in the art from the following description.
상기 과제를 해결하기 위한 본 발명의 일 실시예에 따른 아토피 피부염의 개선 또는 치료용 한방 조성물은 고삼 3-5 중량부, 괴화 3-5 중량부, 황금 4-6 중량부, 백지 4-6 중량부, 노회 3-5 중량부, 해동피 3-5 중량부 및 연교 5-7 중량부를 포함하는 혼합물의 열수 추출물의 증류액을 포함한다.An oriental medicine composition for improving or treating atopic dermatitis according to an embodiment of the present invention for solving the above problems is 3-5 parts by weight of high ginseng, 3-5 parts by weight of ginseng, 4-6 parts by weight of gold, 4-6 parts by weight of white paper It contains the distillate of the hot water extract of a mixture comprising parts, presbytery, 3-5 parts by weight, haedongpi, 3-5 parts by weight, and softwood, 5-7 parts by weight.
상기 조성물은 상기 열수 추출물을, 상기 증류액 70-90 중량부 대비 10-30 중량부로 더 포함할 수 있다.The composition may further include the hot water extract in an amount of 10-30 parts by weight based on 70-90 parts by weight of the distillate.
또한, 상기 혼합물은, 두충 4-6 중량부, 작약 4-6 중량부, 목향 1-3 중량부, 당귀 1-3 중량부, 진피 1-3 중량부, 회향 4-6 중량부, 건강 5-7 중량부, 후박 3-5 중량부, 국화 4-6 중량부, 갈근 4-6 중량부, 지모 4-6 중량부, 곡기생 1-3 중량부, 황백 5-7 중량부, 고본 3-5 중량부, 대황 3-5 중량부, 치자 3-5 중량부, 토봉령 3-5 중량부 및 삼백초 5-7 중량부로 이루어진 군에서 선택되는 하나 이상을 더 포함할 수도 있다.In addition, the mixture contains 4-6 parts by weight of duchung, 4-6 parts by weight of peony, 1-3 parts by weight of mulberry, 1-3 parts by weight of angelicasis, 1-3 parts by weight of dermis, 4-6 parts by weight of fennel, health 5 -7 parts by weight, 3-5 parts by weight of sagebrush, 4-6 parts by weight of chrysanthemum, 4-6 parts by weight of chrysanthemum, 4-6 parts by weight of ginseng root, 4-6 parts by weight of ginseng, 1-3 parts by weight of ginseng, 5-7 parts by weight of Hwangbaek, Gobon 3 -5 parts by weight, 3-5 parts by weight of rhubarb, 3-5 parts by weight of gardenia, 3-5 parts by weight of Tobongryeong, and 5-7 parts by weight of Sambaekcho may further include one or more selected from the group consisting of.
한편, 상기 과제를 해결하기 위한 본 발명의 다른 실시예에 따른 아토피 피부염의 개선 또는 치료용 한방 조성물은 고삼 열수 추출물의 증류액 3-5 중량부, 괴화 열수 추출물의 증류액 3-5 중량부, 황금 열수 추출물의 증류액 4-6 중량부, 백지 열수 추출물의 증류액 4-6 중량부, 노회 열수 추출물의 증류액 3-5 중량부, 해동피 열수 추출물의 증류액 3-5 중량부 및 연교 열수 추출물의 증류액 5-7 중량부를 포함한다.On the other hand, the oriental medicine composition for improving or treating atopic dermatitis according to another embodiment of the present invention for solving the above problems is 3-5 parts by weight of a distillate of hot ginseng extract, 3-5 parts by weight of a distillate of hot water extract of Gossam, 4-6 parts by weight of distillate of golden hot water extract, 4-6 parts by weight of distillate of white paper hot water extract, 3-5 parts by weight of distillate of presbytery hot water extract, 3-5 parts by weight of distillate of haedongpi hot water extract and Yeongyo hot water 5-7 parts by weight of the distillate of the extract.
상기 조성물은 두충 열수 추출물의 증류액 4-6 중량부, 작약 열수 추출물의 증류액 4-6 중량부, 목향 열수 추출물의 증류액 1-3 중량부, 당귀 열수 추출물의 증류액 1-3 중량부, 진피 열수 추출물의 증류액 1-3 중량부, 회향 열수 추출물의 증류액 4-6 중량부, 건강 열수 추출물의 증류액 5-7 중량부, 후박 열수 추출물의 증류액 3-5 중량부, 국화 열수 추출물의 증류액 4-6 중량부, 갈근 열수 추출물의 증류액 4-6 중량부, 지모 열수 추출물의 증류액 4-6 중량부, 곡기생 열수 추출물의 증류액 1-3 중량부, 황백 열수 추출물의 증류액 5-7 중량부, 고본 열수 추출물의 증류액 3-5 중량부, 대황 열수 추출물의 증류액 3-5 중량부, 치자 열수 추출물의 증류액 3-5 중량부, 토봉령 열수 추출물의 증류액 3-5 중량부 및 삼백초 열수 추출물의 증류액 5-7 중량부로 이루어진 군에서 선택되는 하나 이상을 더 포함할 수 있다.The composition comprises 4-6 parts by weight of distillate of Duchung hot water extract, 4-6 parts by weight of distillate of peony hot water extract, 1-3 parts by weight of distillate of Mokhyang hot water extract, and 1-3 parts by weight of distillate of Angelica hot water extract. , 1-3 parts by weight of distillate of dermis hot water extract, 4-6 parts by weight of distillate of fennel hot water extract, 5-7 parts by weight of distillate of health hot water extract, 3-5 parts by weight of distillate of husk hot water extract, chrysanthemum 4-6 parts by weight of the distillate of the hot water extract, 4-6 parts by weight of the distillate of the ginseng root hot water extract, 4-6 parts by weight of the distillate of the Zimo hot water extract, 1-3 parts by weight of the distillate of the Gokgisaeng hot water extract, Hwangbaek hot water 5-7 parts by weight of distillate of extract, 3-5 parts by weight of distillate of Gobon hot water extract, 3-5 parts by weight of distillate of rhubarb hot water extract, 3-5 parts by weight of distillate of gardenia hot water extract, Tobongryeong hot water extract It may further include at least one selected from the group consisting of 3-5 parts by weight of the distillate and 5-7 parts by weight of the distillate of the triticale hot water extract.
상기 다른 과제를 해결하기 위한 본 발명의 일 실시예에 따른 아토피 피부염의 개선 또는 치료용 한방 조성물의 제조 방법은 (a) 고삼 3-5 중량부, 괴화 3-5 중량부, 황금 4-6 중량부, 백지 4-6 중량부, 노회 3-5 중량부, 해동피 3-5 중량부 및 연교 5-7 중량부를 포함하는 혼합물을 열수 추출하여 추출물을 얻는 단계, 및 (b) 상기 추출물을 가열하여 생성된 증기를 냉각시켜 증류액을 수득하는 단계를 포함한다.The method of manufacturing an oriental medicine composition for improvement or treatment of atopic dermatitis according to an embodiment of the present invention for solving the above other problems is (a) 3-5 parts by weight of high ginseng, 3-5 parts by weight of ginseng, 4-6 parts by weight of gold parts, 4-6 parts by weight of white paper, 3-5 parts by weight of presbytery, 3-5 parts by weight of haedongpi, and 5-7 parts by weight of yeonkyo to obtain an extract by hot water extraction, and (b) heating the extract and cooling the resulting vapor to obtain a distillate.
상기 제조 방법은 (c) 상기 가열 후 잔류한 추출물 10-30 중량부를 상기 증류액 70-90 중량부에 혼합하는 단계를 더 포함할 수 있다.The manufacturing method may further include (c) mixing 10-30 parts by weight of the extract remaining after the heating to 70-90 parts by weight of the distillate.
한편, 상기 (a) 단계는, 상기 고삼, 괴화, 황금, 백지, 노회, 해동피 및 연교를 정제수에 투입하고 추출기를 사용하여 80-100 ℃로 8-48시간 동안 가열하는 단계, 및 상기 가열된 것을 여과하여 상기 추출물을 얻는 단계를 포함할 수 있다.On the other hand, in step (a), the high ginseng, gooseberry, gold, white paper, presbytery, haedongpi and Yeongyo are put in purified water and heated to 80-100 ° C. for 8-48 hours using an extractor, and the heated It may include the step of obtaining the extract by filtration.
몇몇 실시예에서, 상기 (b) 단계는, 상기 추출물을 90-100 ℃로 가열하여 생성된 증기를 4-10 ℃의 냉각수관으로 액화시키는 단계, 및 상기 액화된 것을 8,000-14,000 rpm 및 2-8 ℃에서 10-50분간 원심분리하여 고형분을 제거하고 상등액을 취하여 상기 증류액을 수득하는 단계를 포함할 수 있다.In some embodiments, the step (b) may include heating the extract to 90-100° C. and liquefying the steam produced by 4-10° C. cooling water pipe, and liquefying the liquefied product at 8,000-14,000 rpm and 2- It may include the step of removing the solid by centrifugation at 8 ° C. for 10-50 minutes, and taking the supernatant to obtain the distillate.
또한, 상기 (a) 단계에서, 두충 4-6 중량부, 작약 4-6 중량부, 목향 1-3 중량부, 당귀 1-3 중량부, 진피 1-3 중량부, 회향 4-6 중량부, 건강 5-7 중량부, 후박 3-5 중량부, 국화 4-6 중량부, 갈근 4-6 중량부, 지모 4-6 중량부, 곡기생 1-3 중량부, 황백 5-7 중량부, 고본 3-5 중량부, 대황 3-5 중량부, 치자 3-5 중량부, 토봉령 3-5 중량부 및 삼백초 5-7 중량부로 이루어진 군에서 선택되는 하나 이상을 더 혼합하여 열수 추출할 수 있다.In addition, in step (a), 4-6 parts by weight of duchung, 4-6 parts by weight of peony, 1-3 parts by weight of mulberry, 1-3 parts by weight of angelica, 1-3 parts by weight of dermis, 4-6 parts by weight of fennel , Health 5-7 parts by weight, Hucchini 3-5 parts by weight, Chrysanthemum 4-6 parts by weight, Root Root 4-6 parts by weight, Zinc 4-6 parts by weight, Grain ginseng 1-3 parts by weight, Hwangbaek 5-7 parts by weight , 3-5 parts by weight of Gobon, 3-5 parts by weight of rhubarb, 3-5 parts by weight of gardenia, 3-5 parts by weight of Tobongryeong and 5-7 parts by weight of Sambaekcho by further mixing at least one selected from the group consisting of hot water extraction can
상기 과제를 해결하기 위한 본 발명의 다른 실시예에 따른 아토피 피부염의 개선 또는 치료용 한방 조성물의 제조 방법은 (a) 고삼, 괴화, 황금, 백지, 황백, 고본, 해동피 및 연교를 각각 열수 추출하여 각각의 추출물을 얻는 단계, (b) 상기 각 추출물을 가열하여 생성된 증기를 냉각시켜 각각의 증류액을 수득하는 단계 및 (c) 상기 고삼의 증류액 3-5 중량부, 괴화의 증류액 3-5 중량부, 황금의 증류액 4-6 중량부, 백지의 증류액 4-6 중량부, 노회의 증류액 3-5 중량부, 해동피의 증류액 3-5 중량부 및 연교의 증류액 5-7 중량부를 서로 혼합하는 단계를 포함한다.A method of manufacturing an oriental medicine composition for improvement or treatment of atopic dermatitis according to another embodiment of the present invention for solving the above problems is (a) hot water extraction of Gosam, Goehwa, Gold, White paper, Hwangbaek, Gobon, Haedongpi and Yeongyo, respectively. Obtaining each extract, (b) heating each extract to cool the produced vapor to obtain each distillate, and (c) 3-5 parts by weight of the distillate of high ginseng, distillate 3 of Gohwa -5 parts by weight, 4-6 parts by weight of distillate of gold, 4-6 parts by weight of distillate of white paper, 3-5 parts by weight of distillate of presbytery, 3-5 parts by weight of distillate of thawed blood and 5 parts of distillate of Yeongyo -7 parts by weight are mixed with each other.
이때 상기 (a) 단계는, 상기 고삼, 괴화, 황금, 백지, 노회, 해동피 및 연교 각각을 정제수에 투입하고 추출기를 사용하여 80-100 ℃로 8-48시간 동안 가열하는 단계, 및 상기 가열된 것을 여과하여 상기 각 추출물을 얻는 단계를 포함할 수 있다.At this time, the step (a) is a step of putting each of the dried ginseng, Gohwa, gold, white paper, presbytery, haedongpi and Yeongyo in purified water and heating it to 80-100 ° C. for 8-48 hours using an extractor, and the heated It may include the step of obtaining each extract by filtration.
또한, 상기 (b) 단계는, 상기 각 추출물을 90-100 ℃로 가열하여 생성된 증기를 4-10 ℃의 냉각수관으로 액화시키는 단계, 및 상기 액화된 것을 8,000-14,000 rpm 및 2-8 ℃에서 10-50분간 원심분리하여 고형분을 제거하고 상등액을 취하여 상기 각 증류액을 수득하는 단계를 포함할 수 있다.In addition, the step (b) is a step of liquefying the steam produced by heating each extract to 90-100 ℃ with a cooling water pipe of 4-10 ℃, and 8,000-14,000 rpm and 2-8 ℃ of the liquefied It may include the step of removing the solid content by centrifugation for 10-50 minutes and taking the supernatant to obtain each of the distillates.
한편, 상기 (c) 단계에서, 두충의 증류액 4-6 중량부, 작약의 증류액 4-6 중량부, 목향의 증류액 1-3 중량부, 당귀의 증류액 1-3 중량부, 진피의 증류액 1-3 중량부, 회향의 증류액 4-6 중량부, 건강의 증류액 5-7 중량부, 후박의 증류액 3-5 중량부, 국화의 증류액 4-6 중량부, 갈근의 증류액 4-6 중량부, 지모의 증류액 4-6 중량부, 곡기생의 증류액 1-3 중량부, 황백의 증류액 5-7 중량부, 고본의 증류액 3-5 중량부, 대황의 증류액 3-5 중량부, 치자의 증류액 3-5 중량부, 토봉령의 증류액 3-5 중량부 및 삼백초의 증류액 5-7 중량부로 이루어진 군에서 선택되는 하나 이상을 더 혼합하되, 상기 두충 내지 삼백초의 증류액은 상기 (a) 및 (b) 단계와 동일한 방법으로 수득할 수 있다.On the other hand, in step (c), 4-6 parts by weight of distillate of duchung, 4-6 parts by weight of distillate of peony, 1-3 parts by weight of distillate of mulberry, 1-3 parts by weight of distillate of angelicae, dermis 1-3 parts by weight of distillate, 4-6 parts by weight of distillate of fennel, 5-7 parts by weight of distillate of health, 3-5 parts by weight of distillate of husk, 4-6 parts by weight of distillate of chrysanthemum, garlic root 4-6 parts by weight of the distillate, 4-6 parts by weight of the distillate of Zimo, 1-3 parts by weight of the distillate of Gokgi-saeng, 5-7 parts by weight of the distillate of Hwangbaek, 3-5 parts by weight of the distillate of Gobon; At least one selected from the group consisting of 3-5 parts by weight of distillate of rhubarb, 3-5 parts by weight of distillate of gardenia, 3-5 parts by weight of distillate of Tobongryeong and 5-7 parts by weight of distillate of Sambaekcho is further mixed However, the distillate of the duchung to three hundred seconds can be obtained in the same manner as in steps (a) and (b).
상기 실시예들에 따른 아토피 피부염의 개선 또는 치료용 한방 조성물의 제조 방법은 수득한 증류액을 한외 여과막 또는 크로마토그래피를 이용하여 추가적으로 정제하는 단계를 더 포함할 수 있다.The method for preparing an oriental medicine composition for improving or treating atopic dermatitis according to the above embodiments may further include further purifying the obtained distillate using an ultrafiltration membrane or chromatography.
한편, 상술한 증류액 또는 상등액의 밀도는 약 1 kg/L, 즉 정제수의 밀도와 근사하거나 실질적으로 동일할 수 있다. 따라서, 상술한 증류액 또는 상등액의 함량 단위인 '중량부(parts by weight)'는 '부피부(parts by volume)'와 실질적으로 동일한 단위일 수 있다.Meanwhile, the density of the above-described distillate or supernatant may be approximately 1 kg/L, that is, approximately or substantially the same as the density of purified water. Accordingly, 'parts by weight', which is the content unit of the above-described distillate or supernatant, may be substantially the same as 'parts by volume'.
기타 실시예의 구체적인 사항들은 상세한 설명에 포함되어 있다.Details of other embodiments are included in the detailed description.
본 발명의 실시예들에 따른 한방 조성물은 천연 복합성분을 함유하여 항염 및 항산화 활성이 강력하고, 각질형성세포(keratinocyte)에 대한 독성이 없으며, 장기 보존 안정성이 우수하여 피부 자극을 유발할 수 있는 화학 방부제, 첨가제 등의 사용을 피할 수 있어, 아토피 피부염의 개선 또는 치료에 사용하기 적합하다.The oriental medicine composition according to the embodiments of the present invention contains natural complex ingredients, so it has strong anti-inflammatory and antioxidant activity, is non-toxic to keratinocytes, and has excellent long-term storage stability, which can cause skin irritation. Since the use of preservatives and additives can be avoided, it is suitable for use in the improvement or treatment of atopic dermatitis.
본 발명의 실시예들에 따른 효과는 이상에서 예시된 내용에 의해 제한되지 않으며, 더욱 다양한 효과들이 본 명세서 내에 포함되어 있다.Effects according to the embodiments of the present invention are not limited by the contents exemplified above, and more various effects are included in the present specification.
도 1은 본 발명의 일 실험예에 따라 본 발명의 한방 조성물의 각질형성세포(keratinocyte cell)에 대한 독성을 측정한 그래프이다.1 is a graph measuring the toxicity to keratinocyte cells of the oriental medicine composition of the present invention according to an experimental example of the present invention.
도 2는 본 발명의 일 실험예에 따라 본 발명의 한방 조성물의 산화질소(NO)의 생성량 감소 활성을 측정한 그래프이다.Figure 2 is a graph measuring the amount of nitric oxide (NO) production reduction activity of the oriental herbal composition of the present invention according to an experimental example of the present invention.
도 3는 본 발명의 일 실험예에 따라 본 발명의 한방 조성물의 염증성 사이토카인(IL-8, TNF-α)에 대한 감소 활성을 측정한 그래프이다.3 is a graph measuring the reduction activity of the inflammatory cytokines (IL-8, TNF-α) of the herbal composition of the present invention according to an experimental example of the present invention.
본 발명의 이점 및 특징, 그리고 그것들을 달성하는 방법은 상세하게 후술되어 있는 실시예들을 참조하면 명확해질 것이다. 그러나 본 발명은 이하에서 개시되는 실시예들에 한정되는 것이 아니라 서로 다른 다양한 형태로 구현될 것이며, 단지 실시예들은 본 발명의 개시가 완전하도록 하며, 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자에게 발명의 범주를 완전하게 알려주기 위해 제공되는 것이며, 본 발명은 청구항의 범주에 의해 정의될 뿐이다.Advantages and features of the present invention, and methods for achieving them, will become apparent with reference to the embodiments described below in detail. However, the present invention is not limited to the embodiments disclosed below, but will be implemented in various different forms, and only the embodiments allow the disclosure of the present invention to be complete, and those of ordinary skill in the art to which the present invention pertains. It is provided to fully inform the person of the scope of the invention, and the present invention is only defined by the scope of the claims.
본 명세서에서 사용된 용어는 실시예들을 설명하기 위한 것이며 본 발명을 제한하고자 하는 것은 아니다. 본 명세서에서, '및/또는'은 언급된 아이템들의 각각 및 하나 이상의 모든 조합을 포함한다. 또, 단수형은 문구에서 특별히 언급하지 않는 한 복수형도 포함한다. 명세서에서 사용되는 '포함한다(comprises)' 및/또는 '포함하는(comprising)'은 언급된 구성요소 외에 하나 이상의 다른 구성요소의 존재 또는 추가를 배제하지 않는다. '-' 또는 '내지'를 사용하여 나타낸 수치 범위는 다른 언급이 없는 한 그 앞과 뒤에 기재된 값을 각각 하한과 상한으로서 포함하는 수치 범위를 나타낸다. '약' 또는 '대략'은 그 뒤에 기재된 값 또는 수치 범위의 20% 이내의 값 또는 수치 범위를 의미한다.The terminology used herein is for the purpose of describing the embodiments and is not intended to limit the present invention. In this specification, 'and/or' includes each and every combination of one or more of the recited items. The singular also includes the plural, unless the phrase specifically states otherwise. As used herein, 'comprises' and/or 'comprising' does not exclude the presence or addition of one or more other elements in addition to the stated elements. Numerical ranges indicated using '-' or 'to' indicate a numerical range including the values listed before and after as the lower and upper limits, respectively, unless otherwise stated. 'About' or 'approximately' means a value or numerical range within 20% of the value or numerical range recited thereafter.
또한, 본 발명의 실시예의 구성 요소를 설명하는 데 있어서, 제1, 제2, A, B, (a), (b) 등의 용어를 사용할 수 있다. 이러한 용어는 그 구성 요소를 다른 구성 요소와 구별하기 위한 것일 뿐, 그 용어에 의해 해당 구성 요소의 본질이나 차례 또는 순서 등이 한정되지 않는다.In addition, in describing the components of the embodiment of the present invention, terms such as first, second, A, B, (a), (b), etc. may be used. These terms are only for distinguishing the elements from other elements, and the essence, order, or order of the elements are not limited by the terms.
다른 정의가 없다면, 본 명세서에서 사용되는 모든 용어(기술 및 과학적 용어를 포함)는 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자에게 공통적으로 이해될 수 있는 의미로 사용될 수 있을 것이다. 또 일반적으로 사용되는 사전에 정의되어 있는 용어들은 명백하게 특별히 정의되어 있지 않는 한 이상적으로 또는 과도하게 해석되지 않는다.Unless otherwise defined, all terms (including technical and scientific terms) used herein may be used with the meaning commonly understood by those of ordinary skill in the art to which the present invention belongs. In addition, terms defined in a commonly used dictionary are not to be interpreted ideally or excessively unless clearly defined in particular.
그리고 본 발명의 실시예를 설명함에 있어, 관련된 공지 구성 또는 기능에 대한 구체적인 설명이 본 발명의 실시예에 대한 이해를 방해한다고 판단되는 경우에는 그 상세한 설명은 생략한다.In the description of the embodiment of the present invention, if it is determined that a detailed description of a related known configuration or function interferes with the understanding of the embodiment of the present invention, the detailed description thereof will be omitted.
본 명세서에서, '예방'이란 질환 또는 질병을 보유하고 있다고 진단된 적은 없으나, 이러한 질환 또는 질병에 걸릴 수 있는 개체에서 질환 또는 질병의 발생을 억제하는 것을 의미한다. As used herein, the term 'prevention' refers to inhibiting the occurrence of a disease or disease in an individual who has never been diagnosed with a disease or disease, but may be afflicted with such disease or disease.
본 명세서에서, '치료' 또는 '개선'이란 개체에서 (a) 질환 또는 질병의 발전(악화)의 억제, (b) 질환 또는 질병의 경감, 또는 (c) 질환 또는 질환의 제거를 의미한다. As used herein, 'treatment' or 'improvement' refers to (a) inhibition of the development (exacerbation) of a disease or disease, (b) alleviation of the disease or disease, or (c) elimination of the disease or disease in an individual.
본 명세서에서, '개체'란 본 발명의 조성물을 투여하여 증상이 호전될 수 있는 질환을 가진 인간을 포함한 포유동물을 의미한다.As used herein, the term 'subject' refers to a mammal, including a human, having a disease whose symptoms can be improved by administering the composition of the present invention.
본 발명의 한방 조성물은 아토피 피부염에 대한 개선 또는 치료 효능을 갖는 것으로서, 본 명세서에서 '아토피 피부염'이란 아토피성의 피부염, 피부질환, 건선, 습진, 가려움증 등을 모두 포함하는 넓은 의미로 사용된다.The oriental medicinal composition of the present invention has an improvement or therapeutic effect on atopic dermatitis, and in the present specification, 'atopic dermatitis' is used in a broad sense including atopic dermatitis, skin disease, psoriasis, eczema, itching, and the like.
본 발명의 한방 조성물은 액상 추출물, 농축 액상 추출물, 동결건조 분말 및 분무건조 분말로 이루어진 군에서 선택되는 하나 이상의 제형으로 구성될 수 있다. 구체적으로, 본 발명의 한방 조성물은 경피 흡수제(외용피부연고제), 물비누, 비누, 에센스, 젤, 액체세정료, 로션, 폼, 유연수, 화장수, 클렌징폼, 클렌징로션, 클렌징크림, 팩, 맛사지 크림, 에몰리언트(emollient)크림, 에몰리언트(emollient)로션, 화장수에센스, 수렴화장수(astringent), 수용성 리퀴드, 파운데이션, 메이크업베이스, 바디용로션, 수렴화장수, 유연화장수, 영양 화장수, 트리트먼트, 스킨로션, 밀크로션, 영양로션, 영양에센스, 수중유(O/W)형 및 유중수(W/O)형으로 이루어진 군에서 선택되는 하나 이상의 제형일 수 있다.The herbal composition of the present invention may be composed of one or more formulations selected from the group consisting of a liquid extract, a concentrated liquid extract, a freeze-dried powder, and a spray-dried powder. Specifically, the herbal composition of the present invention is a transdermal absorbent (external skin ointment), water soap, soap, essence, gel, liquid detergent, lotion, foam, soft water, lotion, cleansing foam, cleansing lotion, cleansing cream, pack, massage cream , emollient cream, emollient lotion, lotion essence, astringent, water-soluble liquid, foundation, makeup base, body lotion, astringent lotion, softening lotion, nourishing lotion, treatment, skin lotion, milk It may be one or more formulations selected from the group consisting of lotions, nutritional lotions, nutritional essences, oil-in-water (O/W) types and water-in-oil (W/O) types.
본 발명의 한방 조성물은 상기 제형 전체 조성에 대하여 0.005-95 wt%로 포함될 수 있다.The herbal composition of the present invention may be included in an amount of 0.005-95 wt% based on the total composition of the formulation.
이하, 본 발명의 실시예들을 제조예와 실험예를 통해 상세하게 설명하나, 본 발명의 효과가 하기 실험예에 의해 제한되지 아니함은 자명하다.Hereinafter, embodiments of the present invention will be described in detail through Preparation Examples and Experimental Examples, but it is apparent that the effect of the present invention is not limited by the following Experimental Examples.
제조예: 본 발명의 한방 조성물의 제조Preparation Example: Preparation of the herbal composition of the present invention
실시예 1Example 1
고삼 40 g, 괴화 40 g, 황금 50 g, 백지 50 g, 노회 40 g, 해동피 40 g 및 연교 60 g의 한약재 원료들을 정제수로 충분히 세척한 후 혼합하였다. 정제수 20 L를 채운 열탕 증류기에 한약재 원료들을 투입하고 약 80-100 ℃로 30시간 동안 가열하여 열수 추출물을 얻었다. 추출에 사용된 한약재들은 여과하여 제거하고, 열수 추출물을 약 90-100 ℃로 가열하면서 약 4-10 ℃의 냉각수관을 이용하여 증류액을 획득하였다. 증류액을 12,000 rpm 및 4 ℃에서 30분간 원심분리하여 고형분을 제거하고 상등액을 취하여 한방 조성물을 제조하였다.40 g of dried ginseng, 40 g of ginseng, 50 g of gold, 50 g of white paper, 40 g of presbytery, 40 g of haedongpi and 60 g of yeonkyo were thoroughly washed with purified water and then mixed. Herbal medicine raw materials were put into a boiling water still filled with 20 L of purified water and heated at about 80-100° C. for 30 hours to obtain a hot water extract. Herbal medicines used for extraction were removed by filtration, and a distillate was obtained using a cooling water tube of about 4-10 °C while heating the hot water extract to about 90-100 °C. The distillate was centrifuged at 12,000 rpm and 4° C. for 30 minutes to remove solids, and a supernatant was taken to prepare an oriental medicine composition.
실시예 2Example 2
상기 실시예 1에서 가열 후 잔류한 열수 추출물 3 L를 상기 증류액 7 L와 혼합하여 원심분리한 점을 제외하고 상기 실시예 1과 동일한 방법으로 한방 조성물을 제조하였다.An herbal composition was prepared in the same manner as in Example 1, except that 3 L of the hot water extract remaining after heating in Example 1 was mixed with 7 L of the distillate and centrifuged.
실시예 3Example 3
한약재 원료로서 두충 50 g, 작약 50 g, 목향 20 g, 당귀 20 g, 진피 20 g, 회향 50 g, 건강 60 g, 후박 40 g, 국화 50 g, 갈근 50 g, 지모 50 g, 곡기생 20 g, 황백 60 g, 고본 40 g 및 삼백초 60 g를 더 사용한 점을 제외하고 상기 실시예 1과 동일한 방법으로 한방 조성물을 제조하였다.As a raw material for herbal medicines, 50 g of daffodil, 50 g of peony, 20 g of mulberry, 20 g of angelica, 20 g of ginseng, 50 g of fennel, 60 g of health, 40 g of green peppercorns, 50 g of chrysanthemum, 50 g of ginseng root, 50 g of ginseng root, 20 g of ginseng g, Hwangbaek 60 g, Gobon 40 g, and Sambaekcho 60 g, except that an oriental medicine composition was prepared in the same manner as in Example 1 above.
실시예 4Example 4
고삼, 괴화, 황금, 백지, 노회, 해동피 및 연교의 한약재 원료들을 정제수로 충분히 세척한 후, 각 원료를 정제수 20 L를 채운 열탕 증류기에 별개로 투입하고 약 80-100 ℃로 30시간 동안 가열하여 각각의 열수 추출물을 얻었다. 추출에 사용된 한약재들은 여과하여 제거하고, 각 열수 추출물을 약 90-100 ℃로 가열하면서 약 4-10 ℃의 냉각수관을 이용하여 각각의 증류액을 획득하였다. 각 증류액을 12,000 rpm 및 4 ℃에서 30분간 원심분리하여 고형분을 제거하고 각각의 상등액을 취하였다. 고삼 상등액 0.4 L, 괴화 상등액 0.4 L, 황금 상등액 0.5 L, 백지 상등액 0.5 L, 노회 상등액 0.4 L, 해동피 상등액 0.4 L 및 연교 상등액 0.6 L을 서로 혼합하여 한방 조성물을 제조하였다.After thoroughly washing the raw materials of medicinal herbs of ginseng, Gohwa, gold, white paper, presbytery, haedongpi and Yeongyo with purified water, each raw material is separately put into a boiling water still filled with 20 L of purified water and heated at about 80-100 ° C for 30 hours. Each hot water extract was obtained. Herbal medicines used for extraction were removed by filtration, and each distillate was obtained using a cooling water tube of about 4-10 °C while heating each hot water extract to about 90-100 °C. Each distillate was centrifuged at 12,000 rpm and 4° C. for 30 minutes to remove solids, and each supernatant was collected. An oriental medicine composition was prepared by mixing 0.4 L of high ginseng supernatant, 0.4 L of Goehwa supernatant, 0.5 L of golden supernatant, 0.5 L of white paper supernatant, 0.4 L of presbytery supernatant, 0.4 L of Haedongpi supernatant and 0.6 L of Yeongyo supernatant.
실험예 1: 각질형성세포에 대한 독성 평가Experimental Example 1: Evaluation of toxicity to keratinocytes
본 발명의 한방 조성물의 각질형성세포에 대한 독성을 다음과 같이 시험하였다.The toxicity of the oriental herbal composition of the present invention to keratinocytes was tested as follows.
96-well plate를 사용하여 1% FBS(Fetal bovine serum)를 포함하는 DMEM(Dulbecco's modified Eagle's medium) 배지에 인간 각질형성세포(human keratinocyte cell line, HaCaT)를 접종하여 배양하였다. 세포가 배양 접시에 60% 정도 차면 세럼이 들어있지 않은 배지로 바꾸어 16-24시간 배양한 후에 상기 실시예의 조성물을 포함한 배지로 교환해주었다. 48시간 뒤에 MTT(Tetrazolium-based colorimetric) 용액을 10%로 함유한 배지로 교환해주었다. 2-4시간 동안 배양한 뒤 배지를 제거하고 DMSO(Dimethyl sulfoxide)로 배양접시 밑에 남아있는 침전물을 녹여주었다. ELISA leader로 570 nm에서의 흡광도를 측정하고 평균값을 산출하였으며, 그 결과는 도 1과 같았다. 도 1 내지 3에서 D1, D1+E, D2 및 D3는 각각 실시예 1 내지 4의 조성물을 의미한다.Using a 96-well plate, human keratinocyte cell line (HaCaT) was inoculated and cultured in DMEM (Dulbecco's modified Eagle's medium) medium containing 1% Fetal bovine serum (FBS). When the cells were filled to about 60% in the culture dish, the medium was changed to a serum-free medium and cultured for 16-24 hours, and then the medium containing the composition of the above example was exchanged. After 48 hours, it was exchanged with a medium containing 10% MTT (Tetrazolium-based colorimetric) solution. After incubation for 2-4 hours, the medium was removed and the precipitate remaining under the culture dish was dissolved with DMSO (dimethyl sulfoxide). The absorbance at 570 nm was measured with the ELISA leader and the average value was calculated, and the results were as shown in FIG. 1 . 1 to 3, D1, D1+E, D2 and D3 refer to the compositions of Examples 1 to 4, respectively.
도 1에 나타난 바와 같이, 본 발명의 한방 조성물은 각질형성세포에 대한 독성을 나타내지 않음을 알 수 있다.As shown in Figure 1, it can be seen that the oriental medicine composition of the present invention does not show toxicity to keratinocytes.
실험예 2: 항산화 활성 평가Experimental Example 2: Evaluation of antioxidant activity
본 발명의 한방 조성물의 항산화 활성을 평가하기 위해 다음과 같이 산화질소(NO)의 소거능을 시험하였다.In order to evaluate the antioxidant activity of the herbal composition of the present invention, the scavenging ability of nitric oxide (NO) was tested as follows.
10% FBS(fetal bovine serum)과 100 unit/ml의 페니실린 및 스트렙토마이신이 첨가된 DMEM(Dulbecco's modified Eagle's medium) 배지에 Raw 264.7 대식세포를 1×106 cell/ml의 농도로 96-well plate에 접종하고, 37 ℃, 5% CO2에서 하룻밤 동안 배양하였다. 다음날 배지를 제거하고 새로운 배지로 교환한 후, 상기 실시예의 조성물을 50 μl씩 세포에 처리하였다. 30분간 CO2 인큐베이터에서 배양 후 50 μl(1 μg/ml)의 LPS(lipopolysaccharide)를 함유한 배지를 처리하고 인큐베이터(5% CO2, 37 ℃)에서 24시간 동안 배양하였다. 대조군으로서 PBS(phosphate buffered saline)를 사용하였다. Griess reagent I (NED solution)과 Griess reagent II (Sulfaniliamide solution)을 동량으로 혼합하여 넣은 후, 10분간 반응시킨 다음 microplate reader로 540 nm에서의 광밀도(optical density)를 측정하였다. 산화질소(NO)의 농도는 아질산나트륨 (Sodium Nitrate)의 표준곡선(0-100 μM)을 이용하여 계산하였다.Raw 264.7 macrophages in DMEM (Dulbecco's modified Eagle's medium) medium supplemented with 10% FBS (fetal bovine serum) and 100 unit/ml penicillin and streptomycin at a concentration of 1×10 6 cell/ml in a 96-well plate. Inoculated and incubated overnight at 37 °C, 5% CO 2 . The next day, the medium was removed and replaced with a fresh medium, and cells were treated with 50 μl of the composition of the above example. After incubation in a CO 2 incubator for 30 minutes, a medium containing 50 μl (1 μg/ml) of LPS (lipopolysaccharide) was treated and incubated in an incubator (5% CO 2 , 37 ° C.) for 24 hours. As a control, PBS (phosphate buffered saline) was used. Griess reagent I (NED solution) and Griess reagent II (Sulfaniliamide solution) were mixed in equal amounts, and then reacted for 10 minutes, and then optical density at 540 nm was measured with a microplate reader. The concentration of nitric oxide (NO) was calculated using a standard curve (0-100 μM) of sodium nitrite.
도 2에 나타난 바와 같이, 본 발명의 한방 조성물들은 LPS에 의해 촉진된 NO의 생성량을 40-50% 이상 감소시켰기 때문에 우수한 항산화 및 항염 활성이 있음을 알 수 있다.As shown in Figure 2, it can be seen that the oriental herbal compositions of the present invention have excellent antioxidant and anti-inflammatory activity because they reduced the amount of NO produced by LPS by 40-50% or more.
실험예 3: 염증성 사이토카인 생성억제 활성 평가Experimental Example 3: Evaluation of inflammatory cytokine production inhibitory activity
본 발명의 한방 조성물의 항염 활성을 다음과 같은 방법으로 측정하였다. 상기 실험예와 같이 배양한 RAW 264.7 세포에 상기 실시예의 조성물을 먼저 처리한 다음 LPS(lipopolysaccharide)를 1 μg/ml 농도로 처리하여 24시간 배양한 후, 상층액을 회수하여 ELISA 키트로 IL-8(interleukin-8)을 측정하였다. Avidin이 결합된 검출용 항체를 사용하여 반응시킨 후 microplate reader로 450 nm에서 흡광도를 측정하였으며, 대조군으로서 PBS(phosphate buffered saline)를 사용하였다.The anti-inflammatory activity of the herbal composition of the present invention was measured as follows. RAW 264.7 cells cultured as in the above experimental example were first treated with the composition of the above example, then LPS (lipopolysaccharide) was treated at a concentration of 1 μg/ml and cultured for 24 hours, the supernatant was recovered and IL-8 using an ELISA kit. (interleukin-8) was measured. After reacting using an antibody for detection bound to Avidin, absorbance was measured at 450 nm with a microplate reader, and phosphate buffered saline (PBS) was used as a control.
또한, TNF-α 발현을 분석하기 위하여 웨스턴블랏 분석(Western blot analysis)을 수행하였다. 상기 실시예의 조성물이 처리된 배지에서 자란 세포들을 PBS로 씻어내고 0.05% 트립신-EDTA를 처리한 후 원심분리하여 세포를 취한 다음 lysis buffer로 용해한 후, 세포 내 잔사물을 분리시키고 동량의 단백질을 SDS-폴리아크릴아마이드 겔 전기영동(SDS-Polyacrylamide gel elecrophoresis)으로 분리하였다. 분리된 단백질을 니트로섬유소막(nitrocellulose membrane)으로 전이시킨 후, 항체와 2차항체 반응을 실시하고 ECL(enhanced chemiluminoesence) 용액을 처리한 다음 X-ray 필름에 감광시켜 단백질의 발현 정도를 분석하였다.In addition, Western blot analysis was performed to analyze TNF-α expression. The cells grown in the medium treated with the composition of the above example were washed with PBS, treated with 0.05% trypsin-EDTA, centrifuged to take the cells, and then lysed with a lysis buffer, then intracellular residues were separated and the same amount of protein was added to SDS - It was separated by polyacrylamide gel electrophoresis (SDS-Polyacrylamide gel elecrophoresis). After the separated protein was transferred to a nitrocellulose membrane, a secondary antibody reaction was performed with the antibody, treated with an enhanced chemiluminoesence (ECL) solution, and then photosensitized to an X-ray film to analyze the expression level of the protein.
IL-8의 분비량과 TNF-α의 발현량은 도 3과 같았으며, 도 3에 나타난 바와 같이 본 발명의 한방 조성물들은 LPS에 의해 촉진된 염증성 사이토카인인 IL-8과 TNF-α의 생성량을 40-50% 이상 감소시켰기 때문에 우수한 항염 활성이 있음을 알 수 있다.The secretion amount of IL-8 and the expression level of TNF-α were as shown in FIG. 3, and as shown in FIG. 3, the oriental medicine compositions of the present invention showed the production of IL-8 and TNF-α, which are inflammatory cytokines promoted by LPS. It can be seen that there is excellent anti-inflammatory activity because it is reduced by more than 40-50%.
실험예 4: 장기 보존 안정성 평가Experimental Example 4: Long-term storage stability evaluation
본 발명의 한방 조성물의 장기 보존 안정성을 평가하기 위해 다음과 같이 시험하였다. In order to evaluate the long-term storage stability of the herbal composition of the present invention, it was tested as follows.
상기 실시예의 조성물 0.1 ml을 Letheen agar에 도말하고 30 ℃에서 48시간 동안 방치하여 세균 번식 여부를 확인하였고, 상기 실시예의 조성물 0.1 ml을 Sabouraud Dextrose agar에 도말하고 25 ℃에서 72시간 동안 방치하여 진균 번식 여부를 확인하였다. 상기 실시예 조성물의 제조 직후와 방치 이후의 세균 및 진균의 존재를 확인하였다.0.1 ml of the composition of the above example was smeared on Letheen agar and left at 30° C. for 48 hours to check whether or not bacteria were propagated. It was checked whether The presence of bacteria and fungi was confirmed immediately after preparation of the composition of the above example and after leaving it alone.
실험 결과, 상기 실시예 1 내지 4의 조성물들은 제조 직후 뿐만 아니라 방치 이후에도 세균과 진균이 번식하지 않았다. 이와 같이, 본 발명의 한방 조성물은 별도의 방부제 없이 상온에서 장기간 보관하여도 미생물이 번식하지 않아 장기 보관 안정성이 우수하기 때문에, 피부 자극을 유발할 수 있는 화학 방부제, 첨가제 등을 생략할 수 있다.As a result of the experiment, in the compositions of Examples 1 to 4, bacteria and fungi did not propagate immediately after preparation as well as after leaving. As described above, the oriental herbal composition of the present invention has excellent long-term storage stability because microorganisms do not propagate even when stored for a long period at room temperature without a separate preservative, so chemical preservatives and additives that may cause skin irritation can be omitted.
이상에서 본 발명의 실시예를 중심으로 설명하였으나 이는 단지 예시일 뿐 본 발명을 한정하는 것이 아니며, 본 발명이 속하는 분야에서 통상의 지식을 가진 자라면 본 발명의 실시예의 본질적인 특성을 벗어나지 않는 범위에서 이상에 예시되지 않은 여러 가지의 변형과 응용이 가능함을 알 수 있을 것이다. 예를 들어, 본 발명의 실시예에 구체적으로 나타난 각 구성 요소는 변형하여 실시할 수 있다. 그리고 이러한 변형과 응용에 관계된 차이점들은 첨부된 청구 범위에서 규정하는 본 발명의 범위에 포함되는 것으로 해석되어야 할 것이다.In the above, the embodiment of the present invention has been mainly described, but this is only an example and does not limit the present invention. It will be appreciated that various modifications and applications not exemplified above are possible. For example, each component specifically shown in the embodiment of the present invention may be implemented by modification. And differences related to such modifications and applications should be construed as being included in the scope of the present invention defined in the appended claims.
본 발명은 아토피 피부염의 개선 또는 치료용 한방 조성물 및 그 제조 방법에 관한 산업분야에 이용될 수 있다.The present invention can be used in the industrial field related to an oriental medicine composition for improving or treating atopic dermatitis and a method for manufacturing the same.
Claims (14)
- 고삼 3-5 중량부, 괴화 3-5 중량부, 황금 4-6 중량부, 백지 4-6 중량부, 노회 3-5 중량부, 해동피 3-5 중량부 및 연교 5-7 중량부를 포함하는 혼합물의 열수 추출물의 증류액을 포함하는3 to 5 parts by weight of high ginseng, 3-5 parts by weight of ginseng, 4-6 parts by weight of gold, 4-6 parts by weight of white paper, 3-5 parts by weight of presbytery, 3-5 parts by weight of thawed skin, and 5-7 parts by weight of softwood containing the distillate of the hot water extract of the mixture아토피 피부염의 개선 또는 치료용 한방 조성물.An herbal composition for the improvement or treatment of atopic dermatitis.
- 제1 항에 있어서,According to claim 1,상기 열수 추출물을, 상기 증류액 70-90 중량부 대비 10-30 중량부로 더 포함하는The hot water extract further comprising 10-30 parts by weight compared to 70-90 parts by weight of the distillate아토피 피부염의 개선 또는 치료용 한방 조성물.An herbal composition for the improvement or treatment of atopic dermatitis.
- 제1 항에 있어서,According to claim 1,상기 혼합물은, The mixture is두충 4-6 중량부, 작약 4-6 중량부, 목향 1-3 중량부, 당귀 1-3 중량부, 진피 1-3 중량부, 회향 4-6 중량부, 건강 5-7 중량부, 후박 3-5 중량부, 국화 4-6 중량부, 갈근 4-6 중량부, 지모 4-6 중량부, 곡기생 1-3 중량부, 황백 5-7 중량부, 고본 3-5 중량부, 대황 3-5 중량부, 치자 3-5 중량부, 토봉령 3-5 중량부 및 삼백초 5-7 중량부로 이루어진 군에서 선택되는 하나 이상을 더 포함하는4-6 parts by weight of duchung, 4-6 parts by weight of peony, 1-3 parts by weight of mulberry, 1-3 parts by weight of angelicae, 1-3 parts by weight of dermis, 4-6 parts by weight of fennel, 5-7 parts by weight of nutmeg 3-5 parts by weight, 4-6 parts by weight of chrysanthemum, 4-6 parts by weight of rhubarb, 4-6 parts by weight of ginseng, 1-3 parts by weight of grain ginseng, 5-7 parts by weight of white chrysanthemum, 3-5 parts by weight of Gobon, rhubarb 3-5 parts by weight, gardenia 3-5 parts by weight, 3-5 parts by weight of Tobongryeong, and 5-7 parts by weight of three hundred seconds further comprising at least one selected from the group consisting of아토피 피부염의 개선 또는 치료용 한방 조성물.An herbal composition for the improvement or treatment of atopic dermatitis.
- 고삼 열수 추출물의 증류액 3-5 중량부, 괴화 열수 추출물의 증류액 3-5 중량부, 황금 열수 추출물의 증류액 4-6 중량부, 백지 열수 추출물의 증류액 4-6 중량부, 노회 열수 추출물의 증류액 3-5 중량부, 해동피 열수 추출물의 증류액 3-5 중량부 및 연교 열수 추출물의 증류액 5-7 중량부를 포함하는3-5 parts by weight of the distillate of the hot ginseng hot water extract, 3-5 parts by weight of the distillate of the Goehwa hot water extract, 4-6 parts by weight of the distillate of the golden hot water extract, 4-6 parts by weight of the distillate of the white paper hot water extract, hot water of presbytery 3-5 parts by weight of the distillate of the extract, 3-5 parts by weight of the distillate of Haedongpi hot water extract, and 5-7 parts by weight of the distillate of Yeongyo hot water extract아토피 피부염의 개선 또는 치료용 한방 조성물.An herbal composition for the improvement or treatment of atopic dermatitis.
- 제4 항에 있어서,5. The method of claim 4,두충 열수 추출물의 증류액 4-6 중량부, 작약 열수 추출물의 증류액 4-6 중량부, 목향 열수 추출물의 증류액 1-3 중량부, 당귀 열수 추출물의 증류액 1-3 중량부, 진피 열수 추출물의 증류액 1-3 중량부, 회향 열수 추출물의 증류액 4-6 중량부, 건강 열수 추출물의 증류액 5-7 중량부, 후박 열수 추출물의 증류액 3-5 중량부, 국화 열수 추출물의 증류액 4-6 중량부, 갈근 열수 추출물의 증류액 4-6 중량부, 지모 열수 추출물의 증류액 4-6 중량부, 곡기생 열수 추출물의 증류액 1-3 중량부, 황백 열수 추출물의 증류액 5-7 중량부, 고본 열수 추출물의 증류액 3-5 중량부, 대황 열수 추출물의 증류액 3-5 중량부, 치자 열수 추출물의 증류액 3-5 중량부, 토봉령 열수 추출물의 증류액 3-5 중량부 및 삼백초 열수 추출물의 증류액 5-7 중량부로 이루어진 군에서 선택되는 하나 이상을 더 포함하는4-6 parts by weight of distillate of Duchung hot water extract, 4-6 parts by weight of distillate of peony hot water extract, 1-3 parts by weight of distillate of Mokhyang hot water extract, 1-3 parts by weight of distillate of Angelica hot water extract, dermis hot water 1-3 parts by weight of the distillate of the extract, 4-6 parts by weight of the distillate of the fennel hot water extract, 5-7 parts by weight of the distillate of the health hot water extract, 3-5 parts by weight of the distillate of the hot water extract of H. chrysanthemum, of the chrysanthemum hot water extract 4-6 parts by weight of distillate, 4-6 parts by weight of distillate of Galgeun hot water extract, 4-6 parts by weight of distillate of Zymo hot water extract, 1-3 parts by weight of distillate of Gokgisaeng hot water extract, distillation of Hwangbaek hot water extract 5-7 parts by weight of liquid, 3-5 parts by weight of distillate of Gobon hot water extract, 3-5 parts by weight of distillate of rhubarb hot water extract, 3-5 parts by weight of distillate of gardenia hot water extract, distillate of Tobongryeong hot water extract 3-5 parts by weight and 5-7 parts by weight of the distillate of 300 sec. hot water extract further comprising at least one selected from the group consisting of아토피 피부염의 개선 또는 치료용 한방 조성물.An herbal composition for the improvement or treatment of atopic dermatitis.
- (a) 고삼 3-5 중량부, 괴화 3-5 중량부, 황금 4-6 중량부, 백지 4-6 중량부, 노회 3-5 중량부, 해동피 3-5 중량부 및 연교 5-7 중량부를 포함하는 혼합물을 열수 추출하여 추출물을 얻는 단계; 및(a) 3-5 parts by weight of high ginseng, 3-5 parts by weight of ginseng, 4-6 parts by weight of gold, 4-6 parts by weight of white paper, 3-5 parts by weight of presbytery, 3-5 parts by weight of haedongpi, and 5-7 parts by weight of softwood extracting the mixture containing parts with hot water to obtain an extract; and(b) 상기 추출물을 가열하여 생성된 증기를 냉각시켜 증류액을 수득하는 단계를 포함하는(b) heating the extract to cool the resulting vapor to obtain a distillate아토피 피부염의 개선 또는 치료용 한방 조성물의 제조 방법.A method of manufacturing an oriental medicine composition for improving or treating atopic dermatitis.
- 제6 항에 있어서,7. The method of claim 6,(c) 상기 가열 후 잔류한 추출물 10-30 중량부를 상기 증류액 70-90 중량부에 혼합하는 단계를 더 포함하는(c) further comprising mixing 10-30 parts by weight of the extract remaining after the heating with 70-90 parts by weight of the distillate아토피 피부염의 개선 또는 치료용 한방 조성물의 제조 방법.A method of manufacturing an oriental medicine composition for improving or treating atopic dermatitis.
- 제6 항에 있어서,7. The method of claim 6,상기 (a) 단계는,The step (a) is,상기 고삼, 괴화, 황금, 백지, 노회, 해동피 및 연교를 정제수에 투입하고 추출기를 사용하여 80-100 ℃로 8-48시간 동안 가열하는 단계; 및Putting the dried ginseng, Gohwa, gold, white paper, presbytery, haedongpi and Yeongyo in purified water and heating at 80-100° C. for 8-48 hours using an extractor; and상기 가열된 것을 여과하여 상기 추출물을 얻는 단계를 포함하는Filtering the heated thing comprising the step of obtaining the extract아토피 피부염의 개선 또는 치료용 한방 조성물의 제조 방법.A method of manufacturing an oriental medicine composition for improving or treating atopic dermatitis.
- 제6 항에 있어서,7. The method of claim 6,상기 (b) 단계는,The step (b) is,상기 추출물을 90-100 ℃로 가열하여 생성된 증기를 4-10 ℃의 냉각수관으로 액화시키는 단계; 및liquefying the steam produced by heating the extract to 90-100 °C with a cooling water pipe of 4-10 °C; and상기 액화된 것을 8,000-14,000 rpm 및 2-8 ℃에서 10-50분간 원심분리하여 고형분을 제거하고 상등액을 취하여 상기 증류액을 수득하는 단계를 포함하는Centrifuging the liquefied thing at 8,000-14,000 rpm and 2-8 ° C. for 10-50 minutes to remove solids and taking a supernatant to obtain the distillate아토피 피부염의 개선 또는 치료용 한방 조성물의 제조 방법.A method of manufacturing an oriental medicine composition for improving or treating atopic dermatitis.
- 제6 항에 있어서,7. The method of claim 6,상기 (a) 단계에서,In step (a),두충 4-6 중량부, 작약 4-6 중량부, 목향 1-3 중량부, 당귀 1-3 중량부, 진피 1-3 중량부, 회향 4-6 중량부, 건강 5-7 중량부, 후박 3-5 중량부, 국화 4-6 중량부, 갈근 4-6 중량부, 지모 4-6 중량부, 곡기생 1-3 중량부, 황백 5-7 중량부, 고본 3-5 중량부, 대황 3-5 중량부, 치자 3-5 중량부, 토봉령 3-5 중량부 및 삼백초 5-7 중량부로 이루어진 군에서 선택되는 하나 이상을 더 혼합하여 열수 추출하는4-6 parts by weight of duchung, 4-6 parts by weight of peony, 1-3 parts by weight of mulberry, 1-3 parts by weight of angelicae, 1-3 parts by weight of dermis, 4-6 parts by weight of fennel, 5-7 parts by weight of nutmeg 3-5 parts by weight, 4-6 parts by weight of chrysanthemum, 4-6 parts by weight of rhubarb, 4-6 parts by weight of ginseng, 1-3 parts by weight of grain ginseng, 5-7 parts by weight of white chrysanthemum, 3-5 parts by weight of Gobon, rhubarb Hot water extraction by further mixing at least one selected from the group consisting of 3-5 parts by weight, 3-5 parts by weight of gardenia, 3-5 parts by weight of Tobongryeong, and 5-7 parts by weight of Sambaekcho아토피 피부염의 개선 또는 치료용 한방 조성물의 제조 방법.A method of manufacturing an oriental medicine composition for improving or treating atopic dermatitis.
- (a) 고삼, 괴화, 황금, 백지, 노회, 해동피 및 연교를 각각 열수 추출하여 각각의 추출물을 얻는 단계;(a) hot-water extraction of each ginseng, Gohwa, gold, white paper, presbytery, haedongpi and Yeongyo to obtain each extract;(b) 상기 각 추출물을 가열하여 생성된 증기를 냉각시켜 각각의 증류액을 수득하는 단계; 및(b) heating each of the extracts to cool the resulting vapor to obtain each distillate; and(c) 상기 고삼의 증류액 3-5 중량부, 괴화의 증류액 3-5 중량부, 황금의 증류액 4-6 중량부, 백지의 증류액 4-6 중량부, 노회의 증류액 3-5 중량부, 해동피의 증류액 3-5 중량부 및 연교의 증류액 5-7 중량부를 서로 혼합하는 단계를 포함하는(c) 3-5 parts by weight of the distillate of old ginseng, 3-5 parts by weight of the distillate of Gohwa, 4-6 parts by weight of the distillate of gold, 4-6 parts by weight of the distillate of white paper, the distillate of presbytery 3- 5 parts by weight, 3-5 parts by weight of the distillate of Haedongpi, and 5-7 parts by weight of the distillate of Yeongyo.아토피 피부염의 개선 또는 치료용 한방 조성물의 제조 방법.A method of manufacturing an oriental medicine composition for improving or treating atopic dermatitis.
- 제11 항에 있어서,12. The method of claim 11,상기 (a) 단계는,The step (a) is,상기 고삼, 괴화, 황금, 백지, 노회, 해동피 및 연교 각각을 정제수에 투입하고 추출기를 사용하여 80-100 ℃로 8-48시간 동안 가열하는 단계; 및Putting each of the ginseng, Gohwa, gold, white paper, presbytery, haedongpi and Yeongyo in purified water and heating it to 80-100° C. for 8-48 hours using an extractor; and상기 가열된 것을 여과하여 상기 각 추출물을 얻는 단계를 포함하는Filtering the heated one comprising the step of obtaining each extract아토피 피부염의 개선 또는 치료용 한방 조성물의 제조 방법.A method of manufacturing an oriental medicine composition for improving or treating atopic dermatitis.
- 제11 항에 있어서,12. The method of claim 11,상기 (b) 단계는,The step (b) is,상기 각 추출물을 90-100 ℃로 가열하여 생성된 증기를 4-10 ℃의 냉각수관으로 액화시키는 단계; 및liquefying the steam produced by heating each extract to 90-100 °C with a cooling water pipe of 4-10 °C; and상기 액화된 것을 8,000-14,000 rpm 및 2-8 ℃에서 10-50분간 원심분리하여 고형분을 제거하고 상등액을 취하여 상기 각 증류액을 수득하는 단계를 포함하는Centrifuging the liquefied thing at 8,000-14,000 rpm and 2-8 °C for 10-50 minutes to remove solids, and taking the supernatant to obtain each distillate아토피 피부염의 개선 또는 치료용 한방 조성물의 제조 방법.A method of manufacturing an oriental medicine composition for improving or treating atopic dermatitis.
- 제11 항에 있어서,12. The method of claim 11,상기 (c) 단계에서,In step (c),두충의 증류액 4-6 중량부, 작약의 증류액 4-6 중량부, 목향의 증류액 1-3 중량부, 당귀의 증류액 1-3 중량부, 진피의 증류액 1-3 중량부, 회향의 증류액 4-6 중량부, 건강의 증류액 5-7 중량부, 후박의 증류액 3-5 중량부, 국화의 증류액 4-6 중량부, 갈근의 증류액 4-6 중량부, 지모의 증류액 4-6 중량부, 곡기생의 증류액 1-3 중량부, 황백의 증류액 5-7 중량부, 고본의 증류액 3-5 중량부, 대황의 증류액 3-5 중량부, 치자의 증류액 3-5 중량부, 토봉령의 증류액 3-5 중량부 및 삼백초의 증류액 5-7 중량부로 이루어진 군에서 선택되는 하나 이상을 더 혼합하되,4-6 parts by weight of distillate of duchung, 4-6 parts by weight of distillate of peony, 1-3 parts by weight of distillate of mulberry, 1-3 parts by weight of distillate of angelicasis, 1-3 parts by weight of distillate of dermis; 4-6 parts by weight of distillate of fennel, 5-7 parts by weight of distillate of health, 3-5 parts by weight of distillate of ginseng, 4-6 parts by weight of distillate of chrysanthemum, 4-6 parts by weight of distillate of chrysanthemum; 4-6 parts by weight of distillate of Zimo, 1-3 parts by weight of distillate of Gokgisaeng, 5-7 parts by weight of distillate of Hwangbaek, 3-5 parts by weight of distillate of Gobon, 3-5 parts by weight of distillate of rhubarb , At least one selected from the group consisting of 3-5 parts by weight of distillate of gardenia, 3-5 parts by weight of distillate of Tobongryeong and 5-7 parts by weight of distillate of Sambaekcho is further mixed,상기 두충 내지 삼백초의 증류액은 상기 (a) 및 (b) 단계와 동일한 방법으로 수득하는The distillate of Duchung to Sambaekcho is obtained in the same way as in steps (a) and (b).아토피 피부염의 개선 또는 치료용 한방 조성물의 제조 방법.A method of manufacturing an oriental medicine composition for improving or treating atopic dermatitis.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2020-0083344 | 2020-07-07 | ||
| KR1020200083344A KR102490086B1 (en) | 2020-07-07 | 2020-07-07 | Composition for improvement or treatment of atopic dermatitis containing natural complex components and preparing method thereof |
| KR1020200098893A KR102585932B1 (en) | 2020-08-07 | 2020-08-07 | Composition for improvement or treatment of atopic dermatitis containing natural complex components and preparing method thereof |
| KR10-2020-0098893 | 2020-08-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2022010024A1 true WO2022010024A1 (en) | 2022-01-13 |
Family
ID=79553290
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/KR2020/010477 WO2022010024A1 (en) | 2020-07-07 | 2020-08-07 | Herbal composition for alleviating or treating atopic dermatitis, comprising natural composite ingredients, and method for preparing same |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2022010024A1 (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0995451A (en) * | 1995-09-19 | 1997-04-08 | Epuson Medical Kk | Medicine for treating atopic dermatitis |
| KR100879032B1 (en) * | 2007-05-09 | 2009-01-15 | (주)한스킨 | Natural antibacterial extracts and cosmetic composition comprising the extracts |
| KR20110104625A (en) * | 2010-03-17 | 2011-09-23 | 우석대학교 산학협력단 | Manufacturing method of golden hydrolyzed extract showing prevention and improvement effect of atopic dermatitis and cosmetics prepared using the same |
| KR20120032311A (en) * | 2010-09-28 | 2012-04-05 | 한국 한의학 연구원 | Composition for prevention or treatment of atopic dermatitis comprising herbal extract and fermentation product thereof with lactic acid bacteria |
| KR20120061528A (en) * | 2010-12-03 | 2012-06-13 | 이항종 | A composition for treating skin diseases comprising complex extract and a cosmetic using the same |
| KR20130030491A (en) * | 2011-09-19 | 2013-03-27 | 최양원 | Clude drug composition for treatment atopy and acne |
| KR20190014774A (en) * | 2017-08-03 | 2019-02-13 | 김현숙 | Atopic dermatitis remedy and method for producing the same |
-
2020
- 2020-08-07 WO PCT/KR2020/010477 patent/WO2022010024A1/en active Application Filing
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0995451A (en) * | 1995-09-19 | 1997-04-08 | Epuson Medical Kk | Medicine for treating atopic dermatitis |
| KR100879032B1 (en) * | 2007-05-09 | 2009-01-15 | (주)한스킨 | Natural antibacterial extracts and cosmetic composition comprising the extracts |
| KR20110104625A (en) * | 2010-03-17 | 2011-09-23 | 우석대학교 산학협력단 | Manufacturing method of golden hydrolyzed extract showing prevention and improvement effect of atopic dermatitis and cosmetics prepared using the same |
| KR20120032311A (en) * | 2010-09-28 | 2012-04-05 | 한국 한의학 연구원 | Composition for prevention or treatment of atopic dermatitis comprising herbal extract and fermentation product thereof with lactic acid bacteria |
| KR20120061528A (en) * | 2010-12-03 | 2012-06-13 | 이항종 | A composition for treating skin diseases comprising complex extract and a cosmetic using the same |
| KR20130030491A (en) * | 2011-09-19 | 2013-03-27 | 최양원 | Clude drug composition for treatment atopy and acne |
| KR20190014774A (en) * | 2017-08-03 | 2019-02-13 | 김현숙 | Atopic dermatitis remedy and method for producing the same |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2006123887A1 (en) | Composition containing herb medicine for treating atopic dermatitis | |
| KR20090023236A (en) | Composition for treating and/or preventing atopic dermatitis comprising fermented herb product | |
| KR102247772B1 (en) | Use of extracellular vesicles from kefir grain | |
| KR102192317B1 (en) | Composition for Skin Soothing Comprising Exosomes Derived from Natural Extracts | |
| WO2018105926A1 (en) | Anti-allergy composition containing lactobacillus-fermented composite medicinal herb extract as active ingredient | |
| CN113855718A (en) | Artemisia apiacea extract and application thereof | |
| CN113521152B (en) | Anti-dermatitis composition and preparation method and application thereof | |
| KR20090017182A (en) | Composition comprising german chamomile oil for treatment of atopic dermatitis | |
| CN113679765A (en) | Cortex dictamni extract and application thereof | |
| TWI819235B (en) | Fermentation broth of natural raw materials and uses thereof for inhibiting allergic reaction or for enhancing immunity | |
| WO2022010024A1 (en) | Herbal composition for alleviating or treating atopic dermatitis, comprising natural composite ingredients, and method for preparing same | |
| KR20040050622A (en) | Composition for preventing or treating atopic dermatitis and process for preparation thereof | |
| WO2011108907A2 (en) | Composition for relieving pruritus and atopy, containing medicinal herb extracts as active ingredient | |
| CN115414458B (en) | A Chinese medicinal composition for treating hepatitis B, and its preparation method | |
| KR101026873B1 (en) | Mixed medicinal herb extracts having anti-inflammatory activity and cosmetic composition containing the same | |
| KR100670850B1 (en) | Composition containing Gentianae Macrophyllae Radix Extract for treatment hypersensitive skin disease | |
| CN117100801A (en) | Medicinal composition for resisting atopic dermatitis, and preparation method and application thereof | |
| KR102537948B1 (en) | Composition for improvement or treatment of atopic dermatitis containing natural complex components and preparing method thereof | |
| KR102490086B1 (en) | Composition for improvement or treatment of atopic dermatitis containing natural complex components and preparing method thereof | |
| KR20220019161A (en) | Herbal composition for improvement or treatment of atopic dermatitis containing natural complex components and preparing method thereof | |
| KR102537982B1 (en) | Composition for improvement or treatment of severe dermatopathy containing biochemical mineral recombinant complex ingredients and preparing method thereof | |
| KR20220132478A (en) | Composition for improvement or treatment of atopic dermatitis containing index components of crude drugs and preparing method thereof | |
| KR102144566B1 (en) | A composition for preventing or terating atopic dermatitis comprising lycopi herba extract as an active ingredient | |
| KR20040008871A (en) | Composition for protection of skin and improvement of skin diseases and process for preparation thereof | |
| KR101739425B1 (en) | Composition for preventing or improving inflammatory disorders comprising fraction of Oenanthe javanica ethanol extract as effective component |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20944555 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 20944555 Country of ref document: EP Kind code of ref document: A1 |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 20944555 Country of ref document: EP Kind code of ref document: A1 |